肠杆菌科细菌耐药机制以及UPEC对HeLa细胞的致病性研究
|
摘要
目的研究临床分离的产酸克雷伯菌和阴沟肠杆菌对碳青霉烯类抗生素耐药和/或敏感性降低的分子机制。
方法临床分离到一株对碳青霉烯类抗生素耐药的产酸克雷伯菌ZC101和一株对碳青霉烯类抗生素不敏感的阴沟肠杆菌ZY106。采用琼脂稀释法进行抗生素最低抑菌浓度(MIC)的测定。以大肠杆菌EC600或C600作为受体菌进行接合实验。等电聚焦电泳(IEF)检测产酸克雷伯菌ZC101、阴沟肠杆菌ZY106和它们的大肠杆菌接合子产β-内酰胺酶情况。PCR和DNA测序确定耐药基因的基因型。质粒消除实验证实外膜蛋白缺失是否可以引起对碳青霉烯类抗生素感性下降。十二烷基硫酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE)分析产酸克雷伯菌ZC101外膜蛋白表达情况,并对OmpK35和OmpK36基因进行PCR扩增和DNA序列分析。Urea-SDS-PAGE分析阴沟肠杆菌ZY106的外膜蛋白表达情况。
结果亚胺培南、美罗培南和厄他培南对产酸克雷伯菌ZC101的MIC分别为16μg/ml、16μg/ml和128μg/ml;对阴沟肠杆菌ZY106的MIC分别为2μg/ml、4μg/ml和16μg/ml。
接合实验证实产酸克雷伯菌ZC101可将耐药质粒传递给受体菌大肠杆菌EC600,使其对碳青霉烯类抗生素的敏感性明显降低(MIC值至少上升4倍)。产酸克雷伯菌ZC101的bla_(IMP-4)编码质粒被消除后菌株仍然对碳青酶烯类抗生物素有较高的耐药性。阴沟肠杆菌ZY106可将耐药质粒传递给大肠杆菌C600,使碳青霉烯类抗生素的MIC由接合前的≤0.0625μg/ml变为接合后的0.25μg/ml～0.5μg/ml。
IEF、PCR扩增和序列分析证实ZC101产IMP-4型金属β-内酰胺酶和CTX-M-14型超广谱β-内酰胺酶,而转移接合子只产IMP-4。bla_(IMP-4)基因位于大小约3000 bp的Ⅰ类整合子上,该整合子位于大小约55 kb的质粒上。同时证实ZY106中存在IMP-1型金属β-内酰胺酶和CTX-M-3型超广谱β-内酰胺酶,转移接合子只产IMP-1。ZY106还同时携带有质粒介导喹诺酮耐药基因qnrS1,将编码该基因的质粒通过接合试验转移到受体菌大肠杆菌EC600中可使后者对环丙沙星中介耐药(MIC:2μg/ml),。质粒图谱分析发现bla_(IMP-1)位于大小约50 kb的质粒上,qnrS1基因位于大小约60 kb的质粒上。
产酸克雷伯菌ZC101外膜蛋白的SDS-PAGE和ompK35和ompK36基因序列分析发现ZC101由于ompK36基因中存在插入序列IS5而导致OmpK36膜孔蛋白缺失。对阴沟肠杆菌ZY106外膜蛋白进行Urea-SDS-PAGE分析发现有38 kDa蛋白的缺失。
结论
1、质粒介导的IMP-4型金属β-内酰胺酶合并OmpK36膜孔蛋白缺失是引起产酸克雷伯菌ZC101对碳青霉烯类抗生素耐药的主要原因。
2、质粒介导的IMP-1型金属β-内酰胺酶合并外膜蛋白缺失是引起阴沟肠杆菌ZY106对碳青霉烯类抗生素敏感性降低的主要原因,该菌株同时携带有质粒介导的喹诺酮耐药基因qnrS1。
目的了解尿路感染细菌分布情况,分析尿路感染大肠杆菌的耐药性和超广谱β-内酰胺酶(ESBLs)检出率,研究其对头孢菌素和喹诺酮类抗生素的耐药机制;了解尿道致病基因在其中的分布情况;通过HeLa细胞模型筛选尿道致病性大肠杆菌强毒株,分析其对HeLa细胞的致病性。
方法回顾性调查浙江省59家医院2007年细菌分离状况,以及不同地区大肠杆菌ESBLs检出率和耐药性;同时回顾性调查我院2000年～2008年9年间,我院临床标本和尿液标本细菌分离情况、耐药性和ESBLs检出率,比较尿液分离大肠杆菌与不同标本来源的大肠杆菌的耐药性;采用特异性PCR检测耐药菌株的耐药基因,DNA测序后序列与GenBank中已知序列对比确定基因型和基因突变;采用PFGE分析菌株同源性,并通过PCR对尿路感染分离的大肠杆菌进行分子分型;采用PCR检测尿路感染患者分离的大肠杆菌的致病基因,分析致病基因的分布;通过黏附实验和胎盼兰染色对尿路感染患者分离的大肠杆菌进行强致病菌株的初步表型筛选,采用流式细胞术检测强致病菌株诱导HeLa细胞早期凋亡的能力,在电子显微镜观察细胞凋亡形态学改变。
结果2007年浙江省59家医院调查结果显示,大肠杆菌的分离率处与首位;而且浙江省各地区大肠杆菌ESBLs检出率均在50%以上;对头孢菌素的耐药率在45%以上,对喹诺酮类抗生素耐药率最高,达60%以上;我院9年问回顾性调查显示,尿液分离的细菌中大肠杆菌连续九年都处于首位;大肠杆菌的ESBLs的检出率由2000年的7.2%上升到2008年的53.7%;头孢菌素的耐药率也由20%左右上升到50%以上,而环丙沙星和庆大霉素一直处于较高的耐药水平,耐药率分别为70%和60%左右。尿液分离的大肠杆菌的耐药性与其它标本来源的大肠杆菌比较显示,喹诺酮类抗生素和氨基糖苷类抗生素的耐药率基本相同,而尿液分离的大肠杆菌对头孢菌素的耐药率明显低于其它标本分离的大肠杆菌。
通过病例查询,我们选定了28例住院患者,其尿常规检查白细胞均在2+以上,并且有尿路感染的症状。28株尿路感染患者分离的大肠埃希菌中,对头孢噻肟耐药率为64.29%,对环丙沙星的耐药率为71.43%。耐药基因PCR检测和DNA测序分析显示,同时携带CTX-M-15和CTX-M-14基因的有2株,只携带CTX-M-14的有16株。DNA测序分析喹诺酮耐药菌株gyrA和parC发现,在QRDRs存在突变。而且检测2株携带qnr基因,分别为qnrA1和qnrS1。PFGE结果显示,尿液分离的大肠杆菌同源性比较低,只有两株为同一克隆株,PCR分子分型显示以D型为主,占60.71%,其次为B2型,占35.71%。
致病基因PCR检测阳性率最高的为Ⅰ型菌毛基因,为96.43%,只检测到6株usp基因阳性。通过致病表型筛选实验筛选到2株强致病性大肠埃希菌(6N和27N),携带多种致病基因。其中6N菌株携带usp基因,而27N不携带usp基因,其它致病基因与6N相同。PCR分子分型显示,6N属于B2型,而27N属于D型。它们可以在3h破坏大量HeLa细胞,使HeLa死亡;流式细胞仪检测凋亡结果显示,6N菌株在1.5h可以诱导20.75%的HeLa细胞发生早期凋亡,而27N只有1.55%的HeLa细胞发生早期凋亡。电镜结果从形态学证实6N菌株可以快速引起HeLa细胞发生早期凋亡。
结论
1、大肠杆菌在细菌性感染中占有主要地位,尤其是在尿路细菌感染中。
2、大肠杆菌产ESBLs是引起头孢菌素耐药的主要原因,ESBLs的主要基因型是CTX-M-14型。
3、介导喹诺酮耐药的主要是gyrA和parC基因碱基突变引起,并且伴有qnr质粒介导的耐药。
4、携带usp基因的强毒力株可以引起HeLa细胞快速早期凋亡。
Objective
To investigate the mechanisms of carbapenems resistance and/or reduced susceptibility to carbapenems in clinical isolates of Klebsiella oxytoca and Enterobacter cloacae.
Methods
A carbapenem-resistant K.oxytoca ZC101 strain and a carbapenem-non-susceptible E. cloacae ZY106 strain isolated in our hospital were investigated.Minimum inhibitory concentration(MIC) values of various antibiotics were determined by agar dilution method.Conjugation experiment was carried out in mixed broth cultures,and Escherichia coli EC600 or C600 strain was used as recipient.The crudeβ-lactamase extracts of ZC101,ZY106 and their E.coli transconjugants were subjected to analytical isoelectric focusing(IEF).PCRs and DNA sequence analysis were preformed to confirm the genotype of drug resistance genes.Plasmid currying experiment was performed to confirm the attribution of reduced susceptibility to carbapenems.Outer membrane proteins(OMPs) of K.oxytoca ZC101 were isolated and examined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis(SDS-PAGE) and the ompK35 and ompK36 genes were amplified by using PCR and were sequenced.OMPs of E.cloacae ZY106 were isolated and examined by urea-sodium dodecyl sulfate-polyacrylamide gel electrophoresis(Urea-SDS-PAGE).
Results
MICs of imipenem,meropenem and ertapenem for ZC101 were 16μg/ml,16μg/ml, and 128μg/ml,respectively,and those for ZY106 were 2μg/ml,4μg/ml,and 16μg/ml, respectively.
Conjugation study with E.coli EC600 resulted in the transfer of significant reduced carbapenem susceptibility from ZC101(MICs increased at least four-fold).The IMP-4-plasmid eliminated strain of ZC101 still has high resistance against the carbapenems.Conjugation experiments with E coli C600 resulted in the transfer of drug resistance gene from ZY106,and MICs of carbapenems were increased from 0.0625μg/ml to a range of 0.25 to 0.5μg/ml.
IEF,PCRs and DNA sequence analysis confirmed that ZC101 produced IMP-4 metallo-β-lactamase and CTX-M-14 extended-spectrumβ-lactamase,while E.coli transconjugant produced a single IMP-4.Amplification of integron revealed that blaIMP-4 gene located within a class I integron that was carried on a plasmid with a size of approximately 55 kb.Meanwhile,the results of IEF,PCRs and DNA sequence analysis showed that ZY106 produced IMP-1 metallo-β-lactamase and CTX-M-3 extended-spectrumβ-lactamase,but E.coli transconjugant produced a single IMP-1.A plasmid-mediated quinolone resistance determinant qnrS1 was detected in ZY106. Transfer of the qnrS1-encoding-plasmid into E.coli EC600 by conjugation resulted in intermediate resistance to ciprofloxacin(MIC,2μg/ml) in E.coli transconjugant. Plasmid analysis indicated that the bla_(IMP-1) was located in a plasmid with a size of approximately 50 kb while the size of qnrS1-encoding-plasmid was approximately 60 kb.
SDS-PAGE analysis of outer membrane proteins of K.oxytoca ZC101 indicated its lack of OmpK36.Sequence analysis of ompK36 gene of K.oxytoca ZC101 showed disruption by an insertion sequence IS5.Urea-SDS-PAGE analysis of OMPs showed that ZY106 lacked an OMP of approximately 38 kDa.
Conclusions
1.Carbapenem resistance in K.oxytoca ZC101 is mainly due to production of IMP-4 metallo-β-lactamase combined with the loss of the OmpK36.
2.Reduced susceptibility to carbapenems in E.cloacae ZY106 is mainly due to production of IMP-1 metallo-β-lactamase combined with the loss of an OMP.A plasmid-mediated quinolone resistance determinant qnrS1 is detected in the same isolate.
Objectives To investigate the bacteria flora composiotn of the urinary tract(UT) in the UT infected patients;To analyze the drug resistance profile and extended spectrumβ-lactamases(ESBLs) detection rate of the Escherichia coli that caused the urinary tract infection,and to study its drug resistance for cephalosporin and quinolones;To understand the distribution of pathogenic genes in uropathogenic E.coli(UPEC);To screen the high virulent UPEC strains through HeLa cell model and to analyze the pathogenicity of UPEC to HeLa cell.
Methods We retrospectively studied the data of bacteria isolating,ESBLs detection rate from different regions and drug resistant profile from 59 hospitals of Zhejiang Province in 2007.Meanwhile,we investigated the statistical data of bacteria isolated from urine specimen and other clinical specimen,drug resistance and ESBLs detection rate in the past nine years ranging from 2000 to 2008 in our hospital.We have compared the drug resistance of E coli strains isolated from urine specimens with those from other specimens.Drug resistant genes of the resistant strains were detected by specific PCR and the products were sequenced by PCR.Genotypes and mutations of those genes were confirmed by blasting with the known genes in GenBank.Genetic relationship of isolated strains was examined by pulsed field gel electrophoresis(PFGE).Molecular typing of E coli strains isolated from urinary tract infected patients was determined by a PCR method.Virulence genes of those E coli strains were determined by using PCR method to analyze the distribution of pathogenic genes in those E coli strains.The E coli strains with high pathogenicity isolated from urinary tract infected patients were initially screened by using adhesion experiments and Trypan-blue staining.HeLa cell early apoptosis induced by the high pathogenic strains was examined by flow cytometry and the morphology changes were confirmed by using transmission electron microscopy.
Results The results from 59 hospitals of Zhejiang province in 2007 showed that E coli is the most common cause of infection.ESBLs detection rate of E coli from different regions of Zhejiang province is above 50%.The resistance rate against cephalosporins is above 45%,while the resistance rate of quinolones is the highest,above 60%. Retrospective study of data from our hospital in the past nine years indicated that E coli is the most frequently isolated strain from urine specimen for the past nine years.The ESBLs positive E coli strain detection increased from 7.2%in 2000 to 53.7%in 2008. The resistant rate of cephalosporins also increased from 20%to 50%.However, resistance to ciprofloxacin and gentamicin was maintained at high levels since nine years ago,around 70%and 60%respectively.The drug resistant rate against cephalosporins in E coli isolated from urinaray tract specimens is significantly lower than that in the strains isolated from other sources,while the resistant rate against quinolones and aminoglycoside is similar in the strains from different specimen sources.
Through case inquiring,we selected 28 cases of hospitalized patients,who showed a leukocyte level at above ++ by routine urianalysis,and had symptoms of urinary tract infection.Among the 28 E coli strains isolated from the urinary tract infected patients, 64.29%of the isolates were resistant to cefotaxime and 62.49%was resistant to ciprofloxacin.Results of detection of drug resistance by PCR and DNA sequencing indicated that two isolates harbored both CTX-M-15 and CTX-M-14 genes,and 16 isolates only had CTX-M-14 gene.DNA sequence analysis of gyrA and parC in the quinolones resistant strains found that there were several mutations in the QRDRs.The qnr gene in two isolates was detected as qnrA1 and qnrS1,respectively.PFGE analysis showed that the E coli strains isolated from urine specimen had high genetic heterogeneity,with only two strains belonging to the same clone according to PFGE profile.PCR molecular typing indicated that those isolates mainly belong to type D (60.71%),following type B2(35.71%).
TypeⅠpilus gene was the most common virulence gene with a positive rate at about 96.43%,while only six strains were positive for usp gene.We obtained two high virulent isolates through the pathogenic screening experiment(strain 6N and strain 27N). Both strains had various virulence genes.Strain 27N and 6N contained very similar virulence gene profile except that strain 27N did not contain usp gene.PCR molecular typing showed that strain 6N and 27N belonged to group B2 and group D,respectively. Both strains can destroy HeLa cell within 3 hours causing cell death.Results of apoptosis detected by flow cytometer revealed that strain 6N induced 20.75%of HeLa cells to an early stage apoptosis within 1.5 hours.On the other hand,strain 27N induced only 1.55%of HeLa cells to the early stage apoptosis.Morphology changes observed by transmission electron microscopy confirmed that the strain 6N can induce HeLa cells early apoptosis
Conclusions
1.E.coli has an important role in bacterial infection,especially in urinary tract bacterial infection.
2.Resistance of E coli to cephalosporin is mainly caused by the ESBLs production.The primary genotype of ESBLs in E coli is CTX-M-14 type.
3.Resistance to quinolones is mainly caused by the mutations in gyrA and parC gene, along with qnr plasmid mediated drug resistance.
4.High virulent UPEC strain carrying usp gene can induce HeLa cell rapid early apoptosis.
方法临床分离到一株对碳青霉烯类抗生素耐药的产酸克雷伯菌ZC101和一株对碳青霉烯类抗生素不敏感的阴沟肠杆菌ZY106。采用琼脂稀释法进行抗生素最低抑菌浓度(MIC)的测定。以大肠杆菌EC600或C600作为受体菌进行接合实验。等电聚焦电泳(IEF)检测产酸克雷伯菌ZC101、阴沟肠杆菌ZY106和它们的大肠杆菌接合子产β-内酰胺酶情况。PCR和DNA测序确定耐药基因的基因型。质粒消除实验证实外膜蛋白缺失是否可以引起对碳青霉烯类抗生素感性下降。十二烷基硫酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE)分析产酸克雷伯菌ZC101外膜蛋白表达情况,并对OmpK35和OmpK36基因进行PCR扩增和DNA序列分析。Urea-SDS-PAGE分析阴沟肠杆菌ZY106的外膜蛋白表达情况。
结果亚胺培南、美罗培南和厄他培南对产酸克雷伯菌ZC101的MIC分别为16μg/ml、16μg/ml和128μg/ml;对阴沟肠杆菌ZY106的MIC分别为2μg/ml、4μg/ml和16μg/ml。
接合实验证实产酸克雷伯菌ZC101可将耐药质粒传递给受体菌大肠杆菌EC600,使其对碳青霉烯类抗生素的敏感性明显降低(MIC值至少上升4倍)。产酸克雷伯菌ZC101的bla_(IMP-4)编码质粒被消除后菌株仍然对碳青酶烯类抗生物素有较高的耐药性。阴沟肠杆菌ZY106可将耐药质粒传递给大肠杆菌C600,使碳青霉烯类抗生素的MIC由接合前的≤0.0625μg/ml变为接合后的0.25μg/ml～0.5μg/ml。
IEF、PCR扩增和序列分析证实ZC101产IMP-4型金属β-内酰胺酶和CTX-M-14型超广谱β-内酰胺酶,而转移接合子只产IMP-4。bla_(IMP-4)基因位于大小约3000 bp的Ⅰ类整合子上,该整合子位于大小约55 kb的质粒上。同时证实ZY106中存在IMP-1型金属β-内酰胺酶和CTX-M-3型超广谱β-内酰胺酶,转移接合子只产IMP-1。ZY106还同时携带有质粒介导喹诺酮耐药基因qnrS1,将编码该基因的质粒通过接合试验转移到受体菌大肠杆菌EC600中可使后者对环丙沙星中介耐药(MIC:2μg/ml),。质粒图谱分析发现bla_(IMP-1)位于大小约50 kb的质粒上,qnrS1基因位于大小约60 kb的质粒上。
产酸克雷伯菌ZC101外膜蛋白的SDS-PAGE和ompK35和ompK36基因序列分析发现ZC101由于ompK36基因中存在插入序列IS5而导致OmpK36膜孔蛋白缺失。对阴沟肠杆菌ZY106外膜蛋白进行Urea-SDS-PAGE分析发现有38 kDa蛋白的缺失。
结论
1、质粒介导的IMP-4型金属β-内酰胺酶合并OmpK36膜孔蛋白缺失是引起产酸克雷伯菌ZC101对碳青霉烯类抗生素耐药的主要原因。
2、质粒介导的IMP-1型金属β-内酰胺酶合并外膜蛋白缺失是引起阴沟肠杆菌ZY106对碳青霉烯类抗生素敏感性降低的主要原因,该菌株同时携带有质粒介导的喹诺酮耐药基因qnrS1。
目的了解尿路感染细菌分布情况,分析尿路感染大肠杆菌的耐药性和超广谱β-内酰胺酶(ESBLs)检出率,研究其对头孢菌素和喹诺酮类抗生素的耐药机制;了解尿道致病基因在其中的分布情况;通过HeLa细胞模型筛选尿道致病性大肠杆菌强毒株,分析其对HeLa细胞的致病性。
方法回顾性调查浙江省59家医院2007年细菌分离状况,以及不同地区大肠杆菌ESBLs检出率和耐药性;同时回顾性调查我院2000年～2008年9年间,我院临床标本和尿液标本细菌分离情况、耐药性和ESBLs检出率,比较尿液分离大肠杆菌与不同标本来源的大肠杆菌的耐药性;采用特异性PCR检测耐药菌株的耐药基因,DNA测序后序列与GenBank中已知序列对比确定基因型和基因突变;采用PFGE分析菌株同源性,并通过PCR对尿路感染分离的大肠杆菌进行分子分型;采用PCR检测尿路感染患者分离的大肠杆菌的致病基因,分析致病基因的分布;通过黏附实验和胎盼兰染色对尿路感染患者分离的大肠杆菌进行强致病菌株的初步表型筛选,采用流式细胞术检测强致病菌株诱导HeLa细胞早期凋亡的能力,在电子显微镜观察细胞凋亡形态学改变。
结果2007年浙江省59家医院调查结果显示,大肠杆菌的分离率处与首位;而且浙江省各地区大肠杆菌ESBLs检出率均在50%以上;对头孢菌素的耐药率在45%以上,对喹诺酮类抗生素耐药率最高,达60%以上;我院9年问回顾性调查显示,尿液分离的细菌中大肠杆菌连续九年都处于首位;大肠杆菌的ESBLs的检出率由2000年的7.2%上升到2008年的53.7%;头孢菌素的耐药率也由20%左右上升到50%以上,而环丙沙星和庆大霉素一直处于较高的耐药水平,耐药率分别为70%和60%左右。尿液分离的大肠杆菌的耐药性与其它标本来源的大肠杆菌比较显示,喹诺酮类抗生素和氨基糖苷类抗生素的耐药率基本相同,而尿液分离的大肠杆菌对头孢菌素的耐药率明显低于其它标本分离的大肠杆菌。
通过病例查询,我们选定了28例住院患者,其尿常规检查白细胞均在2+以上,并且有尿路感染的症状。28株尿路感染患者分离的大肠埃希菌中,对头孢噻肟耐药率为64.29%,对环丙沙星的耐药率为71.43%。耐药基因PCR检测和DNA测序分析显示,同时携带CTX-M-15和CTX-M-14基因的有2株,只携带CTX-M-14的有16株。DNA测序分析喹诺酮耐药菌株gyrA和parC发现,在QRDRs存在突变。而且检测2株携带qnr基因,分别为qnrA1和qnrS1。PFGE结果显示,尿液分离的大肠杆菌同源性比较低,只有两株为同一克隆株,PCR分子分型显示以D型为主,占60.71%,其次为B2型,占35.71%。
致病基因PCR检测阳性率最高的为Ⅰ型菌毛基因,为96.43%,只检测到6株usp基因阳性。通过致病表型筛选实验筛选到2株强致病性大肠埃希菌(6N和27N),携带多种致病基因。其中6N菌株携带usp基因,而27N不携带usp基因,其它致病基因与6N相同。PCR分子分型显示,6N属于B2型,而27N属于D型。它们可以在3h破坏大量HeLa细胞,使HeLa死亡;流式细胞仪检测凋亡结果显示,6N菌株在1.5h可以诱导20.75%的HeLa细胞发生早期凋亡,而27N只有1.55%的HeLa细胞发生早期凋亡。电镜结果从形态学证实6N菌株可以快速引起HeLa细胞发生早期凋亡。
结论
1、大肠杆菌在细菌性感染中占有主要地位,尤其是在尿路细菌感染中。
2、大肠杆菌产ESBLs是引起头孢菌素耐药的主要原因,ESBLs的主要基因型是CTX-M-14型。
3、介导喹诺酮耐药的主要是gyrA和parC基因碱基突变引起,并且伴有qnr质粒介导的耐药。
4、携带usp基因的强毒力株可以引起HeLa细胞快速早期凋亡。
Objective
To investigate the mechanisms of carbapenems resistance and/or reduced susceptibility to carbapenems in clinical isolates of Klebsiella oxytoca and Enterobacter cloacae.
Methods
A carbapenem-resistant K.oxytoca ZC101 strain and a carbapenem-non-susceptible E. cloacae ZY106 strain isolated in our hospital were investigated.Minimum inhibitory concentration(MIC) values of various antibiotics were determined by agar dilution method.Conjugation experiment was carried out in mixed broth cultures,and Escherichia coli EC600 or C600 strain was used as recipient.The crudeβ-lactamase extracts of ZC101,ZY106 and their E.coli transconjugants were subjected to analytical isoelectric focusing(IEF).PCRs and DNA sequence analysis were preformed to confirm the genotype of drug resistance genes.Plasmid currying experiment was performed to confirm the attribution of reduced susceptibility to carbapenems.Outer membrane proteins(OMPs) of K.oxytoca ZC101 were isolated and examined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis(SDS-PAGE) and the ompK35 and ompK36 genes were amplified by using PCR and were sequenced.OMPs of E.cloacae ZY106 were isolated and examined by urea-sodium dodecyl sulfate-polyacrylamide gel electrophoresis(Urea-SDS-PAGE).
Results
MICs of imipenem,meropenem and ertapenem for ZC101 were 16μg/ml,16μg/ml, and 128μg/ml,respectively,and those for ZY106 were 2μg/ml,4μg/ml,and 16μg/ml, respectively.
Conjugation study with E.coli EC600 resulted in the transfer of significant reduced carbapenem susceptibility from ZC101(MICs increased at least four-fold).The IMP-4-plasmid eliminated strain of ZC101 still has high resistance against the carbapenems.Conjugation experiments with E coli C600 resulted in the transfer of drug resistance gene from ZY106,and MICs of carbapenems were increased from 0.0625μg/ml to a range of 0.25 to 0.5μg/ml.
IEF,PCRs and DNA sequence analysis confirmed that ZC101 produced IMP-4 metallo-β-lactamase and CTX-M-14 extended-spectrumβ-lactamase,while E.coli transconjugant produced a single IMP-4.Amplification of integron revealed that blaIMP-4 gene located within a class I integron that was carried on a plasmid with a size of approximately 55 kb.Meanwhile,the results of IEF,PCRs and DNA sequence analysis showed that ZY106 produced IMP-1 metallo-β-lactamase and CTX-M-3 extended-spectrumβ-lactamase,but E.coli transconjugant produced a single IMP-1.A plasmid-mediated quinolone resistance determinant qnrS1 was detected in ZY106. Transfer of the qnrS1-encoding-plasmid into E.coli EC600 by conjugation resulted in intermediate resistance to ciprofloxacin(MIC,2μg/ml) in E.coli transconjugant. Plasmid analysis indicated that the bla_(IMP-1) was located in a plasmid with a size of approximately 50 kb while the size of qnrS1-encoding-plasmid was approximately 60 kb.
SDS-PAGE analysis of outer membrane proteins of K.oxytoca ZC101 indicated its lack of OmpK36.Sequence analysis of ompK36 gene of K.oxytoca ZC101 showed disruption by an insertion sequence IS5.Urea-SDS-PAGE analysis of OMPs showed that ZY106 lacked an OMP of approximately 38 kDa.
Conclusions
1.Carbapenem resistance in K.oxytoca ZC101 is mainly due to production of IMP-4 metallo-β-lactamase combined with the loss of the OmpK36.
2.Reduced susceptibility to carbapenems in E.cloacae ZY106 is mainly due to production of IMP-1 metallo-β-lactamase combined with the loss of an OMP.A plasmid-mediated quinolone resistance determinant qnrS1 is detected in the same isolate.
Objectives To investigate the bacteria flora composiotn of the urinary tract(UT) in the UT infected patients;To analyze the drug resistance profile and extended spectrumβ-lactamases(ESBLs) detection rate of the Escherichia coli that caused the urinary tract infection,and to study its drug resistance for cephalosporin and quinolones;To understand the distribution of pathogenic genes in uropathogenic E.coli(UPEC);To screen the high virulent UPEC strains through HeLa cell model and to analyze the pathogenicity of UPEC to HeLa cell.
Methods We retrospectively studied the data of bacteria isolating,ESBLs detection rate from different regions and drug resistant profile from 59 hospitals of Zhejiang Province in 2007.Meanwhile,we investigated the statistical data of bacteria isolated from urine specimen and other clinical specimen,drug resistance and ESBLs detection rate in the past nine years ranging from 2000 to 2008 in our hospital.We have compared the drug resistance of E coli strains isolated from urine specimens with those from other specimens.Drug resistant genes of the resistant strains were detected by specific PCR and the products were sequenced by PCR.Genotypes and mutations of those genes were confirmed by blasting with the known genes in GenBank.Genetic relationship of isolated strains was examined by pulsed field gel electrophoresis(PFGE).Molecular typing of E coli strains isolated from urinary tract infected patients was determined by a PCR method.Virulence genes of those E coli strains were determined by using PCR method to analyze the distribution of pathogenic genes in those E coli strains.The E coli strains with high pathogenicity isolated from urinary tract infected patients were initially screened by using adhesion experiments and Trypan-blue staining.HeLa cell early apoptosis induced by the high pathogenic strains was examined by flow cytometry and the morphology changes were confirmed by using transmission electron microscopy.
Results The results from 59 hospitals of Zhejiang province in 2007 showed that E coli is the most common cause of infection.ESBLs detection rate of E coli from different regions of Zhejiang province is above 50%.The resistance rate against cephalosporins is above 45%,while the resistance rate of quinolones is the highest,above 60%. Retrospective study of data from our hospital in the past nine years indicated that E coli is the most frequently isolated strain from urine specimen for the past nine years.The ESBLs positive E coli strain detection increased from 7.2%in 2000 to 53.7%in 2008. The resistant rate of cephalosporins also increased from 20%to 50%.However, resistance to ciprofloxacin and gentamicin was maintained at high levels since nine years ago,around 70%and 60%respectively.The drug resistant rate against cephalosporins in E coli isolated from urinaray tract specimens is significantly lower than that in the strains isolated from other sources,while the resistant rate against quinolones and aminoglycoside is similar in the strains from different specimen sources.
Through case inquiring,we selected 28 cases of hospitalized patients,who showed a leukocyte level at above ++ by routine urianalysis,and had symptoms of urinary tract infection.Among the 28 E coli strains isolated from the urinary tract infected patients, 64.29%of the isolates were resistant to cefotaxime and 62.49%was resistant to ciprofloxacin.Results of detection of drug resistance by PCR and DNA sequencing indicated that two isolates harbored both CTX-M-15 and CTX-M-14 genes,and 16 isolates only had CTX-M-14 gene.DNA sequence analysis of gyrA and parC in the quinolones resistant strains found that there were several mutations in the QRDRs.The qnr gene in two isolates was detected as qnrA1 and qnrS1,respectively.PFGE analysis showed that the E coli strains isolated from urine specimen had high genetic heterogeneity,with only two strains belonging to the same clone according to PFGE profile.PCR molecular typing indicated that those isolates mainly belong to type D (60.71%),following type B2(35.71%).
TypeⅠpilus gene was the most common virulence gene with a positive rate at about 96.43%,while only six strains were positive for usp gene.We obtained two high virulent isolates through the pathogenic screening experiment(strain 6N and strain 27N). Both strains had various virulence genes.Strain 27N and 6N contained very similar virulence gene profile except that strain 27N did not contain usp gene.PCR molecular typing showed that strain 6N and 27N belonged to group B2 and group D,respectively. Both strains can destroy HeLa cell within 3 hours causing cell death.Results of apoptosis detected by flow cytometer revealed that strain 6N induced 20.75%of HeLa cells to an early stage apoptosis within 1.5 hours.On the other hand,strain 27N induced only 1.55%of HeLa cells to the early stage apoptosis.Morphology changes observed by transmission electron microscopy confirmed that the strain 6N can induce HeLa cells early apoptosis
Conclusions
1.E.coli has an important role in bacterial infection,especially in urinary tract bacterial infection.
2.Resistance of E coli to cephalosporin is mainly caused by the ESBLs production.The primary genotype of ESBLs in E coli is CTX-M-14 type.
3.Resistance to quinolones is mainly caused by the mutations in gyrA and parC gene, along with qnr plasmid mediated drug resistance.
4.High virulent UPEC strain carrying usp gene can induce HeLa cell rapid early apoptosis.
引文
1.Queenan AM,Bush K.Carbapenemases:the versatile p-lactamases.Clin Microbiol Rev,2007,20(3):440-458.
2.Peleg AY,Franklin C,Bell JM,et al.Dissemination of the metallo-P-lactamase gene bla_(IMP-4) among gram-negative pathogens in a clinical setting in Australia.Clin Infect Dis,2005,41(11):1549-1556.
3.Herbert S,Halvorsen DS,Leong T,et al.Large outbreak of infection and colonization with gram-negative pathogens carrying the metallo-P-lactamase gene bla_(IMP-4) at a 320-bed tertiary hospital in Australia.Infect Control Hosp Epidemiol,2007,28(1):98-101.
4.Wu JJ,Ko WC,Tsai SH,et al.Prevalence of plasmid-mediated quinolone resistance determinants QnrA,QnrB,and QnrS among clinical isolates of Enterobacter cloacae in a Taiwanese hospital.Antimicrob Agents Chemother,2007,51(4):1223-1227.
5.Liu YF,Yan JJ,Ko WC,et al.Characterization of carbapenem-non-susceptible Escherichia coli isolates from a university hospital in Taiwan.J Antimicrob Chemother,2008,61(5):1020-1023.
6.Wu JJ,Ko WC,Wu HM,et al.Prevalence of Qnr determinants among bloodstream isolates of Escherichia coli and Klebsiella pneumoniae in a Taiwanese hospital,1999-2005.J Antimicrob Chemother,2008,61(6):1234-1239.
7.Koh TH,Babini GS,Woodford N,et al.Carbapenem-hydrolysing BVIP-1 P-lactamase in Klebsiella pneumoniae from Singapore.Lancet,1999,353(9170):2162.
8.Lincopan N,McCulloch JA,Reinert C,et al.First isolation of metallo-P-lactamase-producing multiresistant Klebsiella pneumoniae from a patient in Brazil.J Clin Microbiol,2005,43(1):516-519.
9.Lincopan N,Leis R,Vianello MA,et al.Enterobacteria producing extended-spectrum ~3-1actamases and IMP-1 metallo-β-lactamases isolated from Brazilian hospitals.J Med Microbiol,2006,55(Pt 11):1611-1613.
10.Aktas Z,Bal C,Midilli K,et al.First IMP-l-producing Klebsiella pneumoniae isolate in Turkey.Clin Microbiol Infect,2006,(7):695-696.
11.Deshpande LM,Jones RN,Fritsche TR,et al.Occurrence and characterization of carbapenemase-producing Enterobacteriaceae:report from the SENTRY Antimicrobial Surveillance Program(2000-2004).Microb Drug Resist,2006,12(4):223-230.
12.Woodford N,Dallow JW,Hill RL,et al.Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory.Int J Antimicrob Agents,2007,29(4):456-459.
13.Biendo M,Canarelli B,Thomas D,et al.Successive emergence of extended-spectrum β-lactamase-producing and carbapenemase-producing Enterobacter aerogenes isolates in a university hospital.J Clin Microbiol,2008,46(3):1037-1044.
14.Hawkey PM,Xiong J,Ye H,et al.Occurrence of a new metallo-β-lactamase IMP-4carried on a conjugative plasmid in Citrobacter youngae from the People's Republic of China.FEMS Microbiol Lett,2001,194(1):53-57.
15.骆俊,朱德妹,徐晓刚,等.泛耐药弗劳地柠檬酸杆菌产β内酰 胺酶及同源性.中华传染病杂志,2006,24(5):291-295.
16.Mendes RE,Bell JM,Tumidge JD,et al.Carbapenem-resistant isolates of Klebsiella pneumoniae in China and detection of a conjugative plasmid(blaKPC-2plus qnrB4) and a bla_(IMP-4) gene.Antimicrob Agents Chemother,2008,52(2):798-799.
17.Zhang R,Zhou HW,Cai JC,et al.Plasmid-mediated carbapenem-hydrolysing β-lactamase KPC-2 in carbapenem-resistant Serratia marcescens isolates from Hangzhou,China.J Antimicrob Chemother,2007,59(3):574-576.
18.Zhang R,Yang L,Cai JC,et al.High-level carbapenem resistance in a Citrobacter freundii clinical isolate is due to a combination of KPC-2 production and decreased porin expression.J Med Microbiol,2008,57(3):332-337.
19.蔡加昌,周宏伟,陈功祥,等.一株耐碳青霉烯类的阴沟肠杆菌的KPC检测.中华医学杂志,2008,88(2):135-138.
20.Cai JC,Zhou HW,Zhang R,et al.Emergence of Serratia marcescens,Klebsiella pneumoniae and Escherichia coli possessing the plasmid-mediated carbapenem-hydrolyzing β-lactamase KPC-2 in intensive care units from a Chinese hospital.Antimicrob Agents Chemother,2008,52(6):2014-2018.
21.季淑娟,顾怡明,谭文涛,等.中国部分地区大肠埃希菌和肺炎克雷伯菌超广谱β-内酰胺酶基因型研究.中华检验医学杂志,2004,27(9):590-593.
22.Shibata N,Doi Y,Yamane K,et al.PCR typing of genetic determinants for metallo-β-lactamases and integrases carried by gram-negative bacteria isolated in Japan,with focus on the class 3 integron.J Clin Microbiol.2003,41(12):5407-5413.
23.Levesque C,Piche L,Larose C,et al.PCR mapping of integrons reveals several novel combinations of resistance genes.Antimicrob Agent Chemother,1995,39(1):185-191.
24.Kaczmarek FM,Dib-Hajj F,Shang W,et al.High-Level carbapenem resistance in a Klebsiella pneumoniae clinical isolate is due to the combination of blaACT-1β-lactamase production,porin OmpK35/36 insertional inactivation,and down-regulation of the phosphate transport porin PhoE.Antimicrob Agents Chemother,2006,50(10):3396-3406.
25.Yigit H,Queenan AM,Anderson GJ,et al.Novel carbapenem-hydrolyzing β-lactamase,KPC-1,from a carbapenem-resistant strain of Klebsiella pneumoniae.Antimicrob Agents Chemother,2001,45(4):1151-1161.
26.Foumier B,Roy PH,Lagrange PH,et al.Chromosomal β-lactamase genes of Klebsiella oxytoca are divided into two main groups,blaOXY-1 and blaOXY-2.Antimicrob Agents Chemother,1996,40(2):454-459.
27.Fournier B,Roy PH.Variability of chromosomally encoded β-lactamases from Klebsiella oxytoca.Antimicrob Agents Chemother,1997,41(8):1641-1648.
28.Hemandez-Alles S,Alberti S,Alvarez D,et al.Porin expression in clinical isolates of Klebsiella pneumoniae.Microbiology,1999,145(3):673-679.
1.Queenan AM,Bush K.Carbapenemases:the versatile β-lactamases.Clin Microbiol Rev,2007,20(3):440-458.
2.Peleg AY,Franklin C,Bell JM,et al.Dissemination of the metallo-β-lactamase gene blaIMP-4 among gram-negative pathogens in a clinical setting in Australia.Clin Infect Dis,2005,41(11):1549-1556.
3.Herbert S,Halvorsen DS,Leong T,et al.Large outbreak of infection and colonization with gram-negative pathogens carrying the metallo-β-lactamase gene blaIMP-4 at a 320-bed tertiary hospital in Australia.Infect Control Hosp Epidemiol,2007,28(1):98-101.
4.Wu JJ,Ko WC,Tsai SH,et al.Prevalence of plasmid-mediated quinolone resistance determinants QnrA,QnrB,and QnrS among clinical isolates of Enterobacter cloacae in a Taiwanese hospital.Antimicrob Agents Chemother,2007,51(4):1223-1227.
5.Liu YF,Yan JJ,Ko WC,et al.Characterization of carbapenem-non-susceptible Escherichia coli isolates from a university hospital in Taiwan.J Antimicrob Chemother,2008,61(5):1020-1023.
6.Wu JJ,Ko WC,Wu HM,et al.Prevalence of Qnr determinants among bloodstream isolates of Escherichia coli and Klebsiella pneumoniae in a Taiwanese hospital,1999-2005.J Antimicrob Chemother,2008,61(6):1234-1239.
7.蔡加昌,周宏伟,陈功祥,等.一株耐碳青霉烯类的阴沟肠杆菌的KPC检测.中华医学杂志,2008,88(2):135-138.
8.季淑娟,顾怡明,谭文涛,等.中国部分地区大肠埃希菌和肺炎克雷伯菌超广谱β-内酰胺酶基因型研究.中华检验医学杂志,2004,27(9):590-593.
9.Shibata N,Doi Y,Yamane K,et al.PCR typing of genetic determinants for metallo-β-lactamases and integrases carried by gram-negative bacteria isolated in Japan,with focus on the class 3 integron.J Clin Microbiol.2003,41(12):5407-5413.
10.Robicsek A,Strahilevitz J,Sahm DF,et al.qnr prevalence in ceftazidime-resistant Enterobacteriaceae isolates from the United States.Antimicrob Agents Chemother.2006,50(8):2872-2874.
11.Jiang Y,Zhou Z,Qian Y,et al.Plasmid-mediated quinolone resistance determinants qnr and aac(6')-Ib-cr in extended-spectrum P-lactamase-producing Escherichia coli and Klebsiella pneumoniae in China.J Antimicrob Chemother.2008,61(5):1003-1006.
12.Deguchi T,Yasuda M,Nakano M,Ozeki S,Kanematsu E,Nishino Y,Ishihara S,Kawada Y.Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.J Antimicrob Chemother.1997,40(4):543-549.
13.Lincopan N,McCulloch JA,Reinert C,et al.First isolation of metallo-P-lactamase-producing multiresistant Klebsiella pneumoniae from a patient in Brazil.J Clin Microbiol,2005,43(1):516-519.
14.Zhang R,Zhou HW,Cai JC,et al.Plasmid-mediated carbapenem-hydrolysing β-lactamase KPC-2 in carbapenem-resistant Serratia marcescens isolates from Hangzhou,China.J Antimicrob Chemother,2007,59(3):574-576.
15.Zhang R,Yang L,Cai JC,et al.High-level carbapenem resistance in a Citrobacter freundii clinical isolate is due to a combination of KPC-2 production and decreased porin expression.J Med Microbiol,2008,57(3):332-337.
16.Cai JC,Zhou HW,Zhang R,et al.Emergence of Serratia marcescens,Klebsiella pneumoniae and Escherichia coli possessing the plasmid-mediated carbapenem-hydrolyzing p-lactamase KPC-2 in intensive care units from a Chinese hospital.Antimicrob Agents Chemother,2008,52(6):2014-2018.
1.董光富,叶任高.尿路感染的分类及致病菌.中国社区医师.2003,19(4):6.
2.Nicolle LE.Epidemiology of urinary tract infection.Infect Med 2001,18:153-162.
3.Orrett FA,Premanand N.Bacteriuria in outpatients with chronic indwelling urethral catheters.Med Sci Res 1993,21:333-334.
4.Bukharie HA,Saeed IM.Antimicrobial resistance among pathogens causing acute uncomplicated UTI.Infect Med 2001,18:358-362.
5.Hooton TM,Stamm WE.Diagnosis and treatment of uncomplicated urinary tract infection.Infect Dis Clin North Am 1997,11:551-581.
6.Ik(a|¨)heimo R,Siitonen A,Heiskanen T,K(a|¨)rkk(a|¨)inen U,Kuosmanen P,Lipponen P,M(a|¨)kel(a|¨) PH.Recurrence of urinary tract infection in a primary care setting:analysis of a 1-year follow-up of 179 women.Clin Infect Dis.1996,22(1):91-99.
7.Orrett FA,Davis GK.A comparison of antimicrobial susceptibility profile of urinary pathogens for the years,1999 and 2003.West Indian Med J.2006,55(2):95-99.
8.Gupta K,Hooton TM,Stamm WE.Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections.Ann Intern Med.2001,3;135(1):41-50.
9.Fihn SD.Clinical practice.Acute uncomplicated urinary tract infection in women.N Engl J Med 2003,349:259-66.
10.Gordon KA,Jones RN;SENTRY Participant Groups(Europe,Latin America,North America).Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America:comparison report to Europe and Latin America.Results from the SENTRY Antimicrobial Surveillance Program(2000).Diagn Microbiol Infect Dis.2003,45(4):295-301.
11.娄美萍,林平.尿路感染常见致病菌及其耐药性分析.实用预防医学,2008,15(2):555-557.
12.Gupta K,Hooton TM,Stamm WE.Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections.Ann Intern Med.2001,135(1):41-50.
13.Hooton TM.Fluoroquinolones and resistance in the treatment of uncomplicated urinary tract infection.Int J Antimicrob Agents.2003,22 Suppl 2:65-72.
14.Warren JW,Abrutyn E,Hebel JR,Johnson JR,Schaeffer AJ,Stamm WE.Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women.Infectious Diseases Society of America(IDSA).Clin Infect Dis.1999,29(4):745-58.
15.耿燕,张王刚,王香玲,杨会斌,黄芳,张毅.泌尿系感染产超广谱β内酰胺酶(ESBL S)大肠埃希菌的耐药表型和基因分型.第四军医大学学报,2005,26(7):622-624.
16.Perilli M,Forcella C,Celenza G,Frascaria P,Segatore B,Pellegrini C,Amicosante G.Evidence for qnrB1 and aac(6')-Ib-cr in CTX-M-15-producing uropathogenic Enterobacteriaceae in an Italian teaching hospital.Diagn Microbiol Infect Dis.2009Feb 25.
17.Casson N,Greub G.Resistance of different Chlamydia-like organisms to quinolones and mutations in the quinoline resistance-determining region of the DNA gyrase A-and topoisomerase-encoding genes.Int J Antimicrob Agents.2006,27(6):541-544.
18.Niwa H,Hobo S,Anzai T.A nucleotide mutation associated with fluoroquinolone resistance observed in gyrA of in vitro obtained Rhodococcus equi mutants.Vet Microbiol.2006,15;115(1-3):264-268.
19.Martinez-Martinez L,Pascual A,Jacoby GA.Quinolone resistance from a transferable plasmid.Lancet.1998,14;351(9105):797-799.
20.Song S,Lee EY,Koh EM,Ha HS,Jeong HJ,Bae IK,Jeong SH.Antibiotic Resistance Mechanisms of Escherichia coli Isolates from Urinary Specimens.Korean J Lab Med.2009,29(1):17-24.
21.Robicsek A,Sahm DF,Strahilevitz J,Jacoby GA,Hooper DC.Broader distribution of plasmid-mediated quinolone resistance in the United States.Antimicrob Agents Chemother.2005,49(7):3001-3003.
22.Kaper JB,Nataro JP,Mobley HL.Pathogenic Escherichia coli.Nat Rev Microbiol.2004,2(2):123-40.
23.Kurazono H,Nakano M,Yamamoto S,Ogawa O,Yuri K,Nakata K,Kimura M,Makino S,Nair GB.Distribution of the usp gene in uropathogenic Escherichia coli isolated from companion animals and correlation with serotypes and size-variations of the pathogenicity island.Microbiol Immunol.2003,47(10):797-802.
24.Gaily DL,Leathart J,Blomfield IC.Interaction of FimB and FimE with the fim switch that controls the phase variation of type 1 fimbriae in Escherichia coli K-12.Mol.Microbiol.1996,21:725-738.
25.Mulvey MA,Lopez-Boado YS,Wilson CL,Roth R,Parks WC,Heuser J,Hultgren SJ.Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli.Science 1998,282 (20):1494-1497.
26.Klumpp DJ,Weiser AC,Sengupta S,Forrestal SG,Batler RA,Schaeffer AJ.Uropathogenic Escherichia coli potentiates type 1 pilus-induced apoptosis by suppressing NF-kappaB.Infect Immun.2001,69(11):6689-6695.
27.Klumpp DJ,Rycyk MT,Chen MC,Thumbikat P,Sengupta S,Schaeffer AJ.Uropathogenic Escherichia coli induces extrinsic and intrinsic cascades to initiate urothelial apoptosis.Infect Immun.2006,74(9):5106-5113.
28.Langermann S,Palaszynski S,Barnhart M,Auguste G,Pinkner JS,Burlein J,Barren P,Koenig S,Leath S,Jones CH,Hultgren SJ.Prevention of mucosal Escherichia coli infection by FimH-Based systemic vaccination.Science,1997,276(25):6072.
29.Kurazono H,Yamamoto S,Nakano M,Nair GB,Terai A,Chaicumpa W,Hayashi H.Characterization of a putative virulence island in the chromosome of uropathogenic Escherichia coli possessing a gene encoding a uropathogenic-specific protein.Microb Pathog.2000,28(3):183-189.
30.Yamamoto S,Nakano M,Terai A,Yuri K,Nakata K,Nair GB,Kurazono H,Ogawa O.The presence of the virulence island containing the usp gene in uropathogenic Escherichia coli is associated with urinary tract infection in an experimental mouse model.J Urol.2001,165(4):1347-1351.
1.Orrett FA,Davis GK.A comparison of antimicrobial susceptibility profile of urinary pathogens for the years,1999 and 2003.West Indian Med J.2006,55(2):95-99.
2.Mulvey MA,Lopez-Boado YS,Wilson CL,Roth R,Parks WC,Heuser J,Hultgren SJ.Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli.Science 1998,282(20):1494-1497.
3.Hooton TM,Scholes D,Hughes JP,Winter C,Roberts PL,Stapleton AE,Stergachis A,Stamm WE.A prospective study of risk factors for symptomatic urinary tract infection in young women.N Engl J Med.1996,335(7):468-474.
4.Hooton TM.Fluoroquinolones and resistance in the treatment of uncomplicated urinary tract infection.Int J Antimicrob Agents.2003,Suppl 2:65-72.
5.Kahlmeter G.The ECO-SENS project:a prospective,multinational,multicentre epidemiological survey of the prevalenceand antimicrobial susceptibility of urinary tract pathogensinterim report.J Antimicrob Chemother 2000,46(Suppl.1):15-22.
6.Kahlmeter G.An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections:the ECO.SENS project.J Antimicrob Chemother 2003,51:69-76.
7.耿燕,张王刚,王香玲,杨会斌,黄芳,张毅.泌尿系感染产超广谱β内酰胺酶(ESBL s)大肠埃希菌的耐药表型和基因分型.第四军医大学学报,2005,26(7):622-624.
8.Urban C,Bradford PA,Tuckman M,Segal-Maurer S,Wehbeh W,Grenner L,Colon-Urban R,Mariano N,Rahal JJ.Carbapenem-resistant Escherichia coli harboring Klebsiella pneumoniae carbapenemase beta-lactamases associated with long-term care facilities.
9.傅辉.尿液细菌对常用抗生素耐药的分析.齐齐哈尔医学院学报,2008,29(16):1992.
10.Orrett FA,Davis GK.A comparison of antimicrobial susceptibility profile of urinary pathogens for the years,1999 and 2003.West Indian Med J.2006,55(2):95-99.
11.Hooton TM,Stamm WE.Diagnosis and treatment of uncomplicated urinary tract infection.Infect Dis Clin North Am 1997,11:551-581.
12.陆坚,唐英春,吴本权,张扣兴,张天托,毕筱刚,朱家馨,谈淑卿.华南地区质粒介导超广谱β-内酰胺酶的基因分型研究.中华微生物学和免疫学杂志.2002,22(6):638-643.
13.季淑娟,顾怡明,谭文涛,王丹丹,冯羡菊,周志慧,俞云松,陈亚岗,李兰娟.中国部分地区大肠埃希菌和肺炎克雷伯菌超广谱β内酰胺酶基因型研究.中华检验医学杂志.2004,27(9):590-593.
14.Bonfiglio G,Perilli M,Stefani S,Amicosante G,Nicoletti G.Prevalence of extended spectrum beta-lactamases among Enterobacteriaceae:an Italian survey.Int J Antimicrob Agents.2002,19(3):213-217.
15.Krcmery S,Dubrava M,Krcmery V Jr.Fungal urinary tract infections in patients at risk.Int J Antimicrob Agents.1999,11(3-4):289-291.
1.董光富,叶任高.尿路感染的分类及致病菌.中国社区医师.2003,19(4):6.
2.Foxman B.Epidemiology of urinary tract infections:incidence,morbidity,and economic costs.Am J Med.113(Suppl 1A):5S-13S.
3.Mysorekar IU,Hultgren SJ.Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract.Proc Natl Acad Sci.2006,103(38):14170-14175.
4.Brauner A,Jacobson SH,Kuhn I.Urinary Escherichia coli causing recurrent infections a prospective follow-up of biochemical phenotypes.Clin Nephrol.1992,38(6):318-323.
5.Kurazono H,Nakano M,Yamamoto S,Ogawa O,Yuri K,Nakata K,Kimura M,Makino S,Nair GB.Distribution of the usp gene in uropathogenic Escherichia coli isolated from companion animals and correlation with serotypes and size-variations of the pathogenicity island.Microbiol Immunol.2003,47(10):797-802.
6.Foxman B,Zhang L,Tallman P,Palin K,Rode C,Bloch C,Gillespie B,Marrs CF.Virulence characteristics of Escherichia coli causing first urinary tract infection predict risk of second infection.J Infect Dis.1995,172(6):1536-1541.
7.Johnson DE,Lockatell CV,Russell RG,Hebel JR,Island MD,Stapleton A,Stamm WE,Warren JW.Comparison of Escherichia coli strains recovered from human cystitis and pyelonephritis infections in transurethrally challenged mice.Infect Immun.1998,66(7):3059-3065.
8.Zhang L,Foxman B,Manning SD,Tallman P,Marrs CF.Molecular epidemiologic approaches to urinary tract infection gene discovery in uropathogenic Escherichia coli.Infect Immun.2000,68(4):2009-2015.
9.Johnson JR.Virulence factors in Escherichia coli urinary tract infection.Clin Microbiol Rev.1991,4(1):80-128.
10.Muhldorfer,I.,Ziebuhr,W.,and Hacker,J.Escherichia coli in Urinary Tract Infections.In:Molecular Medical Microbiology.Sussman,M.(ed.) London:Academic Press,2001,pp.1739-1748.
11.Johnson JR,Stell AL.Extended virulence genotypes of Escherichia coli strains from patients with urosepsis in relation to phylogeny and host compromise.J.Infect.Dis.2000,181:261-272.
12.Bidet P,Mahjoub-Messai F,Blanco J,Blanco J,Dehem M,Aujard Y,Bingen E,Bonacorsi S.Combined multilocus sequence typing and O serogrouping distinguishes Escherichia coli subtypes associated with infant urosepsis and/or meningitis.J Infect Dis.2007,196(2):297-303.
13.Lloyd AL,Rasko DA,Mobley HL.Defining genomic islands and uropathogen-specific genes in uropathogenic Escherichia coli.J Bacteriol.2007,189(9):3532-3546.
14.Clermont O,Bonacorsi S,Bingen E.Rapid and simple determination of the Escherichia coli phylogenetic group.Appl Environ Microbiol.2000,66(10):4555-4558.
15.Bingen E,Picard B,Brahimi N,Mathy S,Desjardins P,Elion J,Denamur E.Phylogenetic analysis of Escherichia coli strains causing neonatal meningitis suggests horizontal gene transfer from a predominant pool of highly virulent B2 group strains.J Infect Dis.1998,177(3):642-50.
16.Boyd EF,Hartl DL Chromosomal regions specific to pathogenic isolates of Escherichia coli have a phylogenetically clustered distribution.J Bacteriol.1998,180(5):1159-1165.
17.Johnson JR.Virulence factors in Escherichia coli urinary tract infection.Clin Microbiol Rev.1991,4(1):80-128.
18.Yamamoto S,Nakano M,Terai A,Yuri K,Nakata K,Nair GB,Kurazono H,Ogawa O.The presence of the virulence island containing the usp gene in uropathogenic Escherichia coli is associated with urinary tract infection in an experimental mouse model.J Urol.2001,165(4):1347-1351.
19.Andrews SC,Robinson AK,Rodriguez-Qui(?)ones F.Bacterial iron homeostasis.FEMS Microbiol Rev.2003,27(2-3):215-237.
20.Gunther NW 4th,Snyder JA,Lockatell V,Blomfield I,Johnson DE,Mobley HL.Assessment of virulence of uropathogenic Escherichia coli type 1 fimbrial mutants in which the invertible element is phase-locked on or off.Infect Immun.2002,70(7):3344-3354.
1.Klumpp DJ,Weiser AC,Sengupta S,Forrestal SG,Batler RA,Schaeffer AJ.Uropathogenic Escherichia coli potentiates type 1 pilus-induced apoptosis by suppressing NF-kappaB.Infect Immun.2001,69(11):6689-6695.
2.Klumpp DJ,Rycyk MT,Chen MC,Thumbikat P,Sengupta S,Schaeffer AJ.Uropathogenic Escherichia coli induces extrinsic and intrinsic cascades to initiate urothelial apoptosis.Infect Immun.2006,74(9):5106-5113.
3.Goluszko P,Popov V,Selvarangan R,Nowicki S,Pham T,Nowicki BJ.Dr fimbriae operon of uropathogenic Escherichia coli mediate microtubule-dependent invasion to the HeLa epithelial cell line.J Infect Dis.1997,176(1):158-167.
4.Gomes TA,Abe CM,Marques LR.Detection of HeLa cell-detaching activity and alpha-hemolysin production in enteroaggregative Escherichia coli strains isolated from feces of Brazilian children.J Clin Microbiol.1995,33(12):3364.
5.Marques LR,Abe CM,Griffin PM,Gomes TA.Association between alpha-hemolysin production and HeLa cell-detaching activity in fecal isolates of Escherichia coli.J Clin Microbiol.1995,33(10):2707-2709.
6.Mills M,Meysick KC,O'Brien AD.Cytotoxic necrotizing factor type 1 of uropathogenic Escherichia coli kills cultured human uroepithelial 5637 cells by an apoptotic mechanism.Infect Immun.2000,68(10):5869-5880.
7.De Rycke J,Gonzalez EA,Blanco J,Oswald E,Blanco M,Boivin R.Evidence for two types of cytotoxic necrotizing factor in human and animal clinical isolates of Escherichia coli.J Clin Microbiol.1990,28(4):694-699.
8.Yamamoto S,Nakano M,Terai A,Yuri K,Nakata K,Nair GB,Kurazono H,Ogawa O.The presence of the virulence island containing the usp gene in uropathogenic Escherichia coli is associated with urinary tract infection in an experimental mouse model.J Urol.2001,165(4):1347-1351.
9.Bouzari S,Jafari A,Farhoudi-Moghaddam AA,Shokouhi F,Parsi M.Adherence of non-enteropathogenic Escherichia coli to HeLa cells.J Med Microbiol.1994,40(2):95-97.
10.Okamoto M,Suzuki M,Kitsuda H,Mihira A,Takahashi C,Akiyama S.Adherence to HeLa cells of Escherichia coli isolated from urinary tract infections.Kitasato Arch Exp Med.1986,59(4):105-114.
11.Laestadius A,Richter-Dahlfors A,Aperia A.Dual effects of Escherichia coli alpha-hemolysin on rat renal proximal tubule cells.Kidney Int.2002,62(6):2035-2042.
12.Miraglia AG,Travaglione S,Meschini S,Falzano L,Matarrese P,Quaranta MG,Viora M,Fiorentini C,Fabbri A.Cytotoxic necrotizing factor 1 prevents apoptosis via the Akt/IkB kinase pathway:role of nuclear factor-kappaB and Bcl-2.Mol Biol Cell.2007,18(7):2735-2744.
13.Hertting O,Chromek M,Slamova Z,Kadas L,Soderkvist M,Vainumae I,Tallvik T,Jacobson SH,Brauner A.Cytotoxic necrotizing factor 1 (CNF1) induces an inflammatory response in the urinary tract in vitro but not in vivo.Toxicon.2008,51(8):1544-1547.
14.Davis JM,Carvalho HM,Rasmussen SB,O'Brien AD.Cytotoxic necrotizing factor type 1 delivered by outer membrane vesicles of uropathogenic Escherichia coli attenuates polymorphonuclear leukocyte antimicrobial activity and chemotaxis.Infect Immun.2006,74(8):4401-4408.
1.Nys S,van Merode T,Bartelds AI,Stobberingh EE.Urinary tract infections in general practice patients:diagnostic tests versus bacteriological culture.J Antimicrob Chemother.2006,57(5):955-958.
2.Gupta K,Hooton TM,Stamm WE.Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections.Ann Intern Med.2001,135(1):41-50.
3.娄美萍,林平.尿路感染常见致病菌及其耐药性分析.实用预防医学.2008,15(2):555-557.
4.董光富,叶任高.尿路感染的分类及致病菌.中国社区医师.2003,19(4):6.
5.Foxman B.Epidemiology of urinary tract infections:incidence,morbidity,and economic costs.Am J Med.113(Suppl 1A):5S-13S.
6.Mysorekar IU,Hultgren SJ.Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract.Proc Natl Acad Sci.2006,103(38):14170-14175.
7.Kurazono H,Nakano M,Yamamoto S,Ogawa O,Yuri K,Nakata K,Kimura M,Makino S,Nair GB.Distribution of the usp gene in uropathogenic Escherichia coli isolated from companion animals and correlation with serotypes and size-variations of the pathogenicity island.Microbiol Immunol.2003,47(10):797-802.
8.刘小梅,沈颖.儿童泌尿系感染大肠杆菌耐药现状.北京医学,2008,30(1):32-34.
9.傅辉.尿液细菌对常用抗生素耐药的分析.齐齐哈尔医学院学报,2008,29(16):1992.
10.Orrett FA,Davis GK.A comparison of antimicrobial susceptibility profile of urinary pathogens for the years,1999 and 2003.West Indian Med J.2006,55(2):95-99.
11.Hooton TM,Stature WE.Diagnosis and treatment of uncomplicated urinary tract infection.Infect Dis Clin North Am 1997,11:551-581.
12.Fihn SD.Clinical practice.Acute uncomplicated urinary tract infection in women.N Engl J Med 2003,349:259-266.
13.Talan DA,Stamm WE,Hooton TM,et al.Comparison of ciprofloxacin(7 days) and trimethoprim-sulfamethoxazole(14 days) for acute uncomplicated pyelonephritis in women:a randomized trial.J Am Med Assoc 2000,283:1583-1590.
14.Urban C,Bradford PA,Tuckman M,Segal-Maurer S,Wehbeh W,Grenner L,Colon-Urban R,Mariano N,Rahal JJ.Carbapenem-resistant Escherichia coli harboring Klebsiella pneumoniae carbapenemase beta-lactamases associated with long-term care facilities.Clin Infect Dis.2008,46(11):e127-130.
15.Hooton TM.Fluoroquinolones and resistance in the treatment of uncomplicated urinary tract infection.Int J Antimicrob Agents.2003,Suppl 2:65-72.
16.Kahlmeter G.The ECO-SENS project:a prospective,multinational,multicentre epidemiological survey of the prevalenceand antimicrobial susceptibility of urinary tract pathogensinterim report.J Antimicrob Chemother 2000,46(Suppl.1):15-22.
17.Kahlmeter G.An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections:the ECO.SENS project.J Antimicrob Chemother 2003,51:69-76.
18.Karlowsky JA,Kelly LJ,Thornsberry C,Jones ME,Sahm DF.Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States.Antimicrob Agents Chemother 2002,46(8):2540-2545.
19.Dromigny JA.,Ndoye B.,Macondo EA.,Nabeth P.,Sihy T.,Perrier-Gros-Claud JD.Increasing prevalence of antimicrobial resistance among Enterobacteriaceae uropathogens in Dakar,Senegal:a multicenter study.Diagn Microbiol Infect Dis 2003,47:595-600.
20.Perilli M,Forcella C,Celenza G,Frascaria P,Segatore B,Pellegrini C,Amicosante G.Evidence for qnrB1 and aac(6')-Ib-cr in CTX-M-15-producing uropathogenic Enterobacteriaceae in an Italian teaching hospital.Diagn Microbiol Infect Dis.2009 Feb 25.[Epub ahead of print]
21.Matrat S,Petrella S,Cambau E,Sougakoff W,Jarlier V,Aubry A.Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.Antimicrob Agents Chemother.2007,51 (5):1643-1648.
22.Sorlozano A,Gutierrez J,Jimenez A,de Dios Luna J,Martinez JL.Contribution of a new mutation in parE to quinolone resistance in extended-spectrum-beta-lactamase-producing Escherichia coli isolates.J Clin Microbiol.2007,45(8):2740-2742.
23.Cattoir V,Lesprit P,Lascols C,Denamur E,Legrand P,Soussy CJ,Cambau E.In vivo selection during ofloxacin therapy of Escherichia coli with combined topoisomerase mutations that confer high resistance to ofloxacin but susceptibility to nalidixic acid.J Antimicrob Chemother.2006,58(5):1054-1057.
24.McMurry L,Petrucci RE Jr,Levy SB.Active efflux of tetracycline encoded by four genetically different tetracycline resistance determinants in Escherichia coli.Proc Natl Acad Sci U S A.1980,77(7):3974-3977.
25.Lomovskaya O,Warren MS,Lee A,Galazzo J,Fronko R,Lee M,Blais J,Cho D,Chamberland S,Renau T,Leger R,Hecker S,Watkins W,Hoshino K,Ishida H,Lee VJ.Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa:novel agents for combination therapy.Antimicrob Agents Chemother.2001,45(1):105-116.
26.Mallea M,Mahamoud A,Chevalier J,Alibert-Franco S,Brouant P,Barbe J,Pages JM.Alkylaminoquinolines inhibit the bacterial antibiotic efflux pump in multidrug-resistant clinical isolates.Biochem J.2003,376(Pt 3):801-805.
27.Mazzariol A,Tokue Y,Kanegawa TM,Cornaglia G,Nikaido H.High-level fluoroquinolone-resistant clinical isolates of Escherichia coli overproduce multidrug efflux protein AcrA.Antimicrob Agents Chemother.2000,44(12):3441-3443.
28.Ribera A,Ruiz J,Jiminez de Anta MT,Vila J.Effect of an efflux pump inhibitor on the MIC of nalidixic acid for Acinetobacter baumannii and Stenotrophomonas maltophilia clinical isolates.J Antimicrob Chemother.2002,49(4):697-698.
29.Soto SM,Smithson A,Martinez JA,Horcajada JP,Mensa J,Vila J.Biofilm formation in uropathogenic Escherichia coli strains:relationship with prostatitis,urovirulence factors and antimicrobial resistance.J Urol.2007,177(1):365-368.
30.Landry RM,An D,Hupp JT,Singh PK,Parsek MR.Mucin-Pseudomonas aeruginosa interactions promote biofilm formation and antibiotic resistance.Mol Microbiol.2006,59(1):142-151.
31.Granslo H,Gammelsrud KW,Fredheim EA,Flaegstad T,Klingenberg C.Coagulase-negative staphylococci--biofilm and antibiotic resistance.Tidsskr Nor Laegeforen.2008,128(23):2746-2749.
32.Bradford PA.Extended spectrumbeta lactamases in the 21 st century:characterization,epidemiology,and detection of this important resistance threat.Clin Mierobiol Rev.2001,14(4):933-951.
33.余方友,傅颖媛,胡龙华,贾坤茹,韩立中,倪语星.多重耐药产PER-1型超广谱β内酰胺酶阴沟肠杆菌的研究.中华检验医学杂志.2005,28(6):642-644.
34.蒋晓飞,倪语星.铜绿假单胞菌产生的超广谱β-内酰胺酶.中华微生物学和免疫学杂志.2001,21S:6-8.
35.袁靖,张淑华.产SHV型超广谱β内酰胺酶不动杆菌的检测及其耐药表型和基因型研究.四川生理科学杂志.2003,25(4):176.
36.贾宁,林茂虎,陈世平,索继江,邢玉斌,江朝光.产超广谱β-内酰胺酶变形杆菌的检测.2003,13(3):207-209.
37.Goossens H.MYSTIC program:surmnary of European data from 1997 to 2000.Diagn Micrebiol Infect Dis.2001,41:183-189.
38.Winkur PL,Canton R,Casellas JM,el at.Variations in the prevalence of strains expressing an extended β-spectrum-laetamases phenotype and characterization of imlmes from Europ,the Americas,and the Westem Pacific region.Clin Infect Dis.2001,32(2):94-103.
39.Yu Y,Zhou W,Chen Y,Ding Y,Ma Y.Epidemiological and antibiotic resistant study on extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Zhejiang Province.Chin Med J(Engl).2002,115(10):1479-1482.
40.陈民钧,王辉.中国重症监护病房革兰阴性菌耐药性连续7年监测研究.中华医学杂志.2003,83:375-381.
41.陆坚,唐英春,吴本权,张扣兴,张天托,毕筱刚,朱家馨,谈淑卿.华南地区质粒介导超广谱β-内酰胺酶的基因分型研究.中华微生物学和免疫学杂志.2002,22(6):638-643.
42.刘文恩,王红梅,唐银.产超广谱β-内酰胺酶细菌感染患者治疗与预后的相关性研究.中华医院感染学杂志.2003,13(8):724-726.
43.Dmsano GL Infection in the intensive unit:beta-lactanmses mediated resistaneeamong Entembaetericase and optimal antimicrobial dosing.Clin Infect Dis,1998,27(Supp-):S111-S116.
44.张兵,钟礼立,蔡瑞云,李云,曾赛珍,黄寒,邹润英,王涛.产超广谱β-内酰胺酶细菌感染的危险因素研究.中国当代儿科杂志.2003,5(2):130-132.
45.季淑娟,顾怡明,谭文涛,王丹丹,冯羡菊,周志慧,俞云松,陈亚岗,李兰娟.中国部分地区大肠埃希菌和肺炎克雷伯菌超广谱β内酰胺酶基因型研究.中华检验医学杂志.2004,27(9):590-593.
46.Paterson DL,Mulazimoglu L,Casellas JM,Ko WC,Goossens H,Von Gottberg A,Mohapatra S,Trenholme GM,Klugman KP,McCormack JG,Yu VL.Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia.Clin Infect Dis.2000,30(3):473-478.
47.Yu WL,Jones RN,Hollis RJ,Messer SA,Biedenbach DJ,Deshpande LM,Pfaller MA.Molecular epidemiology of extended-spectrum beta-lactamase-producing,fluoroquinolone-resistant isolates of Klebsiella pneumoniae in Taiwan.J Clin Microbiol.2002 Dec;40(12):4666-4669.
48.Hong T,Moland ES,Abdalhamid B,Hanson ND,Wang J,Sloan C,Fabian D,Farajallah A,Levine J,Thomson KS.Escherichia coli:development of carbapenem resistance during therapy.Clin Infect Dis.2005,40(10):e84-6.
49.Navon-Venezia S,Chmelnitsky I,Leavitt A,Schwaber MJ,Schwartz D,Carmeli Y.Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel.Antimicrob Agents Chemother.2006,50:3098-101.
50.Staplton PD,Shannon KP,French GL.Carbapenem resistance in Escherichia coli associated with plasmid-mediated CMY beta-lactamase production and loss of an outer membrane protein.Antimicrob Agents Chemother.1999,43:1206-1210.
1.董光富,叶任高.尿路感染的分类及致病菌.中国社区医师.2003,19(4):6.
2.Foxman B.Epidemiology of urinary tract infections:incidence,morbidity,and economic costs.Am J Med.113(Suppl 1A):5S-13S.
3.Mysorekar IU,Hultgren SJ.Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract.Proc Natl Acad Sci.2006,103(38):14170-14175.
4.Brauner A,Jacobson SH,Kuhn I.Urinary Escherichia coli causing recurrent infections a prospective follow-up of biochemical phenotypes.Clin Nephrol.1992,38(6):318-323.
5.Kurazono H,Nakano M,Yamamoto S,Ogawa O,Yuri K,Nakata K,Kimura M,Makino S,Nair GB.Distribution of the usp gene in uropathogenic Escherichia coli isolated from companion animals and correlation with serotypes and size-variations of the pathogenicity island.Microbiol Immunol.2003,47(10):797-802.
6.Hacker J,Blum-Oehler G,Muhldorfer I,et al.Pathogenicity islands of virulent bacteria:structure,function and impact on microbial.Mol.Microbiol.1997,23(10):1089-1097.
7.Johnson JR,Stell AL.Extended virulence genotypes of Escherichia coli strains from patients with urosepsis in relation to phylogeny and host compromise.J.Infect.Dis.2000,181:261-272.
8.McDaniel TK,Jarvis KG,Donnenberg MS,Kaper JB.A genetic locus of enterocyte effacement conserved among diverse enterobacterial pathogens.Proc.Natl.Acad.Sci.USA.1995,92(5):1664-1668.
9.Svanborg Eden,C.Bacterial adherence in urinary tract infections caused by Escherichia coli.Scand.J.Urol.Nephrol.1986,20:81-88.
10.Reid G,Sobel JD.Bacterial adherence in the pathogenesis of urinary tract infection:a review.Rev.Infect.Dis.1987,9:470-487.
11.Svanborg Eden C,Hagberg L,Hanson LA,Hull S,Hull R,Jodal U,Leffler H,Lomberg H,Straube E.Bacterial adherence-a pathogenic mechanism in urinary tract infections caused by Escherichia coli.Prog.Allergy.1983,33:175-188.
12.Schilling JD,Mulvey MA,Hultgren SJ.Structure and function of Escherichia coli type 1 pili:new insight into the pathogenesis of urinary tract infections.J Infect Dis.2001,183 (Suppl 1):S36-40.
13.Olsen P B,Klemm P.Localization of promoters in the fim gene cluster and the effect of H-NS on the transcription of fimB and fimE.FEMS Microbiol.Lett.1994,116:95-100.
14.Klemm P.Two regulatory fim genes.fimB and fimE,control the phase variation of type 1 fimbriae in Escherichia coli.EMBO J.1986,5:1389-1393.
15.Hanson MS,Hempel J,Brinton,Jr CC.Purification of the Escherichia coli type 1 pilin and minor pilus proteins and partial characterization of the adhesin protein.J.Bacteriol.1988,170:3350-3358.
16.Klemm P,Christensen G.Three fim genes required for the regulation of length and mediation of adhesion of Escherichia coli type 1 fimbriae.Mol.Gen.Genet.1987,208:439-445.
17.Gaily DL,Leathart J,Blomfield IC.Interaction of FimB and FimE with the fim switch that controls the phase variation of type 1 fimbriae in Escherichia coli K-12.Mol.Microbiol.1996,21:725-738.
18.Mulvey MA,Lopez-Boado YS,Wilson CL,Roth R,Parks WC,Heuser J,Hultgren SJ.Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli.Science 1998,282 (20):1494-1497.
19.Klumpp DJ,Weiser AC,Sengupta S,Forrestal SG,Batler RA,Schaeffer AJ.Uropathogenic Escherichia coli potentiates type 1 pilus-induced apoptosis by suppressing NF-kappaB.Infect Immun.2001,69(11):6689-6695.
20.Klumpp DJ,Rycyk MT,Chen MC,Thumbikat P,Sengupta S,Schaeffer AJ.Uropathogenic Escherichia coli induces extrinsic and intrinsic cascades to initiate urothelial apoptosis.Infect Immun.2006,74(9):5106-5113.
21.Langermann S,Palaszynski S,Barnhart M,Auguste G,Pinkner JS,Burlein J,Barren P,Koenig S,Leath S,Jones CH,Hultgren SJ.Prevention of mucosal Escherichia coli infection by FimH-Based systemic vaccination.Science,1997,276(25):6072.
22.Langermann S,Mollby R,Burlein JE,Palaszynski SR,Auguste CG,DeFusco A,Strouse R,Schenerman MA,Hultgren SJ,Pinkner JS,Winberg J,Guldevall L,Soderhall M,Ishikawa K,Normark S,Koenig S.Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli.J Infect Dis,2000,181 (2):7742778.
23.Johnson JR.Virulence factors in Escherichia coli urinary tract infection.Clin Microbiol Rev.1991,4(1):80-128.
24.Lund B,Lindberg F,Marklund BI.The PapG protein is the α-D-galactopyranosyl[1(1-4)-β-4]-D-galactopyranose-binding adhesin of uropathogenic Escherichia coli.Proc Natl Acad Sd USA.1987,84(16):5898-5902.
25.Brinton CC.The structure,function,synthesis,and genetic control of bacterial pili and a molecular model for DNA and RNA transport in gram negative bacteria.Trans.N.Y.Acad.Sci.1965,27:1003-1054.
26.Holden N,Totsika M,Dixon L,Catherwood K,Gaily DL.Regulation of P-fimbrial phase variation frequencies in Escherichia coli CFT073.Infect Immun.2007,75(7):3325-3334.
27.Lindberg F,Tennent JM,Hultgren SJ,Lund B,Normark S PapD,a periplasmic transport protein in P-pilus biogenesis.J Bacteriol.1989,171:6052-6058
28.Johnson JR,Brown JJ,Ahmed P.Diversity of hemagglutination phenotypes among P-fimbriated wild-type strains of Escherichia coli in relation to papG allele repertoire.Clin Diagn Lab Immunol.1998,5(2):160-170.
29.Wullt B,Bergsten G,Connell H,Rollano P,Gebretsadik N,Hull R,Svanborg C.P fimbriae enhance the early establishment of Escherichia coli in the human urinary tract.Mol Microbiol.2000,38(3):456-464.
30.Tseng CC,Huang JJ,Wang MC,Wu AB,Ko WC,Chen WC,Wu JJ.PapG Ⅱ adhesin in the establishment and persistence of Escherichia coli infection in mouse kidneys.Kidney Int.2007,71(8):764-770.
31.Rice JC,Peng T,Spence JS,Wang HQ,Goldblum RM,Corthesy B,Nowicki BJ.Pyelonephritic Escherichia coli expressing P fimbriae decrease immune response of the mouse kidney.J Am Soc Nephrol.2005,16(12):3583-3591.
32.Pere A,Leinonen M,Vaisanen-Rhen V,Rhen M,Korhonen TK.Occurrence of type-1C fimbriae on Escherichia coli strains isolated from human extraintestinal infections.J Gen Microbiol.1985,131(7):1705-1711.
33.Khan AS,Kniep B,Oelschlaeger TA,Van Die I,Korhonen T,Hacker J.Receptor structure for F1C fimbriae of uropathogenic Escherichia coli.Infect Immun.2000,68(6):3541-3547.
34.Ott M,Hosch(?)tzky H,Jann K,Van Die I,Hacker J.Gene clusters for S fimbrial adhesin (sfa) and F1C fimbriae (foc) of Escherichia coli:comparative aspects of structure and function.J Bacteriol.1988,170(9):3983-3990.
35.Labigne-Roussel A,Falkow S.Distribution and degree of heterogeneity of the afimbrial-adhesin-encoding operon (afa) among uropathogenic Escherichia coli isolates.Infect Immun.1988,56(3):640-648.
36.Pham TQ,Goluszko P,Popov V,Nowicki S,Nowicki BJ.Molecular cloning and characterization of Dr-Ⅱ,a nonfimbrial adhesin-Ⅰ-like adhesin isolated from gestational pyelonephritis-associated Escherichia coli that binds to decay-accelerating factor.Infect Immun.1997,65(10):4309-4318.
37.Foxman B,Zhang L,Tallman P,Palin K,Rode C,Bloch C,Gillespie B,Marrs CF.Virulence characteristics of Escherichia coli causing first urinary tract infection predict risk of second infection.J Infect Dis.1995,172(6):1536-1541.
38.Nowicki B,Selvarangan R,Nowicki S.Family of Escherichia coli Dr adhesins:decay-accelerating factor receptor recognition and invasiveness.J Infect Dis.2001,183 Suppl 1:S24-27.
39.Goluszko P,Popov V,Selvarangan R,Nowicki S,Pham T,Nowicki BJ.Dr fimbriae operon of uropathogenic Escherichia coli mediate microtubule-dependent invasion to the HeLa epithelial cell line.J Infect Dis.1997,176(1):158-167.
40.Smith HW.The haemolysins of Escherichia coli.J Pathol Bacteriol.1963,85:197-211.
41.Walton JR,Smith DH.New hemolysin (gamma) produced by Escherichia coli.J Bacteriol.1969,98(1):304-305.
42.Felmlee T,Pellett S,Welch RA.Nucleotide sequence of an Escherichia coli chromosomal hemolysin.J Bacteriol.1985,163(1):94-105.
43.Bhakdi S,Mackman N,Nicaud JM,Holland IB.Escherichia coli hemolysin may damage target cell membranes by generating transmembrane pores.Infect Immun.1986,2(1):63-69.
44.Jorgensen SE,Mulcahy PF,Wu GK,Louis CF.Calcium accumulation in human and sheep erythrocytes that is induced by Escherichia coli hemolysin.Toxicon.1983,21(5):717-27.
45.Rennie RP,Freer JH,Arbuthnott JP.The kinetics of erythrocyte lysis by Escherichia coli haemolysin.J Med Microbiol.1974,7(2):189-195.
46.Smith YC,Rasmussen SB,Grande KK,Conran RM,O'Brien AD.Hemolysin of uropathogenic Escherichia coli evokes extensive shedding of the uroepithelium and hemorrhage in bladder tissue within the first 24 hours after intraurethral inoculation of mice.Infect Immun.2008.76(7):2978-2990.
47.Smith YC,Grande KK,Rasmussen SB,O'Brien AD.Novel three-dimensional organoid model for evaluation of the interaction of uropathogenic Escherichia coli with terminally differentiated human urothelial cells.Infect Immun.2006,74(1):750-757.
48.Mobley HL,Green DM,Trifillis AL,Johnson DE,Chippendale GR,Lockatell CV,Jones BD,Warren JW.Pyelonephritogenic Escherichia coli and killing of cultured human renal proximal tubular epithelial cells:role of hemolysin in some strains.Infect Immun.1990,58(5):1281-1289.
49.Warren JW,Mobley HL,Hebel JR,Trifillis AL.Cytolethality of hemolytic Escherichia coli to primary human renal proximal tubular cell cultures obtained from different donors.Urology.1995,45(4):706-710.
50.Laestadius A,Richter-Dahlfors A,Aperia A.Dual effects of Escherichia coli alpha-hemolysin on rat renal proximal tubule cells.Kidney Int.2002,62(6):2035-2042.
51.De Rycke J,Gonzalez EA,Blanco J,Oswald E,Blanco M,Boivin R.Evidence for two types of cytotoxic necrotizing factor in human and animal clinical isolates of Escherichia coli.J Clin Microbiol.1990,28(4):694-699.
52.Landraud L,Gauthier M,Fosse T,Boquet P.Frequency of Escherichia coli strains producing the cytotoxic necrotizing factor (CNF1) in nosocomial urinary tract infections.Lett Appl Microbiol.2000,30(3):213-216.
53.Andreu A,Stapleton AE,Fennell C,Lockman HA,Xercavins M,Fernandez F,Stamm WE.Urovirulence determinants in Escherichia coli strains causing prostatitis.J Infect Dis.1997,176(2):464-469.
54.Rippere-Lampe KE,Lang M,Ceri H,Olson M,Lockman HA,O'Brien AD.Cytotoxic necrotizing factor type 1-positive Escherichia coli causes increased inflammation and tissue damage to the prostate in a rat prostatitis model.Infect Immun.2001,69(10):6515-6519.
55.Falzano L,Fiorentini C,Donelli G,Michel E,Kocks C,Cossart P,Cabanie L,Oswald E,Boquet P.Induction of phagocytic behaviour in human epithelial cells by Escherichia coli cytotoxic necrotizing factor type 1.Mol Microbiol.1993,9(6):1247-1254.,
56.Fiorentini C,Fabbri A,Matarrese P,Falzano L,Boquet P,Malorni W.Hinderance of apoptosis and phagocytic behaviour induced by Escherichia coli cytotoxic necrotizing factor 1:two related activities in epithelial cells.Biochem Biophys Res Commun.1997,18;241(2):341-346.
57.Mills M,Meysick KC,O'Brien AD.Cytotoxic necrotizing factor type 1 of uropathogenic Escherichia coli kills cultured human uroepithelial 5637 cells by an apoptotic mechanism.Infect Immun.2000,68(10):5869-5880.
58.Miraglia AG,Travaglione S,Meschini S,Falzano L,Matarrese P,Quaranta MG,Viora M,Fiorentini C,Fabbri A.Cytotoxic necrotizing factor 1 prevents apoptosis via the Akt/IkB kinase pathway:role of nuclear factor-kappaB and Bcl-2.Mol Biol Cell.2007,18(7):2735-2744.
59.Hertting O,Chromek M,Slamova Z,Kadas L,Soderkvist M,Vainumae I,Tallvik T,Jacobson SH,Brauner A.Cytotoxic necrotizing factor 1 (CNF1) induces an inflammatory response in the urinary tract in vitro but not in vivo.Toxicon.2008,51(8):1544-1547.
60.Davis JM,Carvalho HM,Rasmussen SB,O'Brien AD.Cytotoxic necrotizing factor type 1 delivered by outer membrane vesicles of uropathogenic Escherichia coli attenuates polymorphonuclear leukocyte antimicrobial activity and chemotaxis.Infect Immun.2006,74(8):4401-4408.
61.Earhart,C.F.Uptake and metabolism of iron and molybdenum,1996,p.1075-1090.In F.C.Neidhardt (ed.),Escherichia coli and Salmonella.ASM Press,Washington,D.C.
62.Schubert,S.,A.Rakin,H.Karch,E.Carniel,and J.Heeseman.Prevalence of the “high pathogenicity island”of Yersinia species among Escherichia coli strains that are pathogenic to humans.Infect.Immun.1998,66:480-485.
63.Russo TA,Carlino UB,Mong A,Jodush ST.Identification of genes in an extraintestinal isolate of Escherichia coli with increased expression after exposure to human urine.Infect Immun.1999,67(10):5306-5314.
64.Torres AG,Redford P,Welch RA,Payne SM.TonB-dependent systems of uropathogenic Escherichia coli:aerobactin and heme transport and TonB are required for virulence in the mouse.Infect Immun.2001,69(10):6179-6185.
65.Jann K,Jann B.Capsules of Escherichia coli,expression and biological significance.Can J Microbiol.1992,38(7):705-710.
66.Whitfield C,Roberts IS.Structure,assembly and regulation of expression of capsules in Escherichia coli.Mol Microbiol.1999,31(5):1307-13019.
67.Tiba MR,Yano T,Leite Dda S.Genotypic characterization of virulence factors in Escherichia coli strains from patients with cystitis.Rev Inst Med Trop Sao Paulo.2008,50(5):255-260.
68.Schneider G,Dobrindt U,Br(?)ggemann H,Nagy G,Janke B,Blum-Oehler G,Buchrieser C,Gottschalk G,Emody L,Hacker J.The pathogenicity island-associated K15 capsule determinant exhibits a novel genetic structure and correlates with virulence in uropathogenic Escherichia coli strain 536.Infect Immun.2004 Oct;72(10):5993-6001.
69.Kubori T,Matsushima Y,Nakamura D,Uralil J,Lara-Tejero M,Sukhan A,Galan JE,Aizawa SI.Supramolecular structure of the Salmonella typhimurium type Ⅲ protein secretion system.Science.1998,280(5363):602-605.
70.Miyazaki J,Ba-Thein W,Kumao T,Akaza H,Hayashi H.Identification of a type Ⅲ secretion system in uropathogenic Escherichia coli.FEMS Microbiol Lett.2002,212(2):221-228.
71.Nakano M,Yamamoto S,Terai A,Ogawa O,Makino SI,Hayashi H,Nair GB,Kurazono H.Structural and sequence diversity of the pathogenicity island of uropathogenic Escherichia coli which encodes the USP protein.FEMS MicrobiolLett.2001,205(1):71-76.
72.Kurazono H,Yamamoto S,Nakano M,Nair GB,Terai A,Chaicumpa W,Hayashi H.Characterization of a putative virulence island in the chromosome of uropathogenic Escherichia coli possessing a gene encoding a uropathogenic-specific protein.Microb Pathog.2000,28(3):183-189.
73.Yamamoto S,Nakano M,Terai A,Yuri K,Nakata K,Nair GB,Kurazono H,Ogawa O.The presence of the virulence island containing the usp gene in uropathogenic Escherichia coli is associated with urinary tract infection in an experimental mouse model.J Urol.2001,165(4):1347-1351.
74.Nicoletti M,Superti F,Conti C,Calconi A,Zagaglia C.Virulence factors of lactose-negative Escherichia coli strains isolated from children with diarrhea in Somalia.J Clin Microbiol.1988,26(3):524-529.
2.Peleg AY,Franklin C,Bell JM,et al.Dissemination of the metallo-P-lactamase gene bla_(IMP-4) among gram-negative pathogens in a clinical setting in Australia.Clin Infect Dis,2005,41(11):1549-1556.
3.Herbert S,Halvorsen DS,Leong T,et al.Large outbreak of infection and colonization with gram-negative pathogens carrying the metallo-P-lactamase gene bla_(IMP-4) at a 320-bed tertiary hospital in Australia.Infect Control Hosp Epidemiol,2007,28(1):98-101.
4.Wu JJ,Ko WC,Tsai SH,et al.Prevalence of plasmid-mediated quinolone resistance determinants QnrA,QnrB,and QnrS among clinical isolates of Enterobacter cloacae in a Taiwanese hospital.Antimicrob Agents Chemother,2007,51(4):1223-1227.
5.Liu YF,Yan JJ,Ko WC,et al.Characterization of carbapenem-non-susceptible Escherichia coli isolates from a university hospital in Taiwan.J Antimicrob Chemother,2008,61(5):1020-1023.
6.Wu JJ,Ko WC,Wu HM,et al.Prevalence of Qnr determinants among bloodstream isolates of Escherichia coli and Klebsiella pneumoniae in a Taiwanese hospital,1999-2005.J Antimicrob Chemother,2008,61(6):1234-1239.
7.Koh TH,Babini GS,Woodford N,et al.Carbapenem-hydrolysing BVIP-1 P-lactamase in Klebsiella pneumoniae from Singapore.Lancet,1999,353(9170):2162.
8.Lincopan N,McCulloch JA,Reinert C,et al.First isolation of metallo-P-lactamase-producing multiresistant Klebsiella pneumoniae from a patient in Brazil.J Clin Microbiol,2005,43(1):516-519.
9.Lincopan N,Leis R,Vianello MA,et al.Enterobacteria producing extended-spectrum ~3-1actamases and IMP-1 metallo-β-lactamases isolated from Brazilian hospitals.J Med Microbiol,2006,55(Pt 11):1611-1613.
10.Aktas Z,Bal C,Midilli K,et al.First IMP-l-producing Klebsiella pneumoniae isolate in Turkey.Clin Microbiol Infect,2006,(7):695-696.
11.Deshpande LM,Jones RN,Fritsche TR,et al.Occurrence and characterization of carbapenemase-producing Enterobacteriaceae:report from the SENTRY Antimicrobial Surveillance Program(2000-2004).Microb Drug Resist,2006,12(4):223-230.
12.Woodford N,Dallow JW,Hill RL,et al.Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory.Int J Antimicrob Agents,2007,29(4):456-459.
13.Biendo M,Canarelli B,Thomas D,et al.Successive emergence of extended-spectrum β-lactamase-producing and carbapenemase-producing Enterobacter aerogenes isolates in a university hospital.J Clin Microbiol,2008,46(3):1037-1044.
14.Hawkey PM,Xiong J,Ye H,et al.Occurrence of a new metallo-β-lactamase IMP-4carried on a conjugative plasmid in Citrobacter youngae from the People's Republic of China.FEMS Microbiol Lett,2001,194(1):53-57.
15.骆俊,朱德妹,徐晓刚,等.泛耐药弗劳地柠檬酸杆菌产β内酰 胺酶及同源性.中华传染病杂志,2006,24(5):291-295.
16.Mendes RE,Bell JM,Tumidge JD,et al.Carbapenem-resistant isolates of Klebsiella pneumoniae in China and detection of a conjugative plasmid(blaKPC-2plus qnrB4) and a bla_(IMP-4) gene.Antimicrob Agents Chemother,2008,52(2):798-799.
17.Zhang R,Zhou HW,Cai JC,et al.Plasmid-mediated carbapenem-hydrolysing β-lactamase KPC-2 in carbapenem-resistant Serratia marcescens isolates from Hangzhou,China.J Antimicrob Chemother,2007,59(3):574-576.
18.Zhang R,Yang L,Cai JC,et al.High-level carbapenem resistance in a Citrobacter freundii clinical isolate is due to a combination of KPC-2 production and decreased porin expression.J Med Microbiol,2008,57(3):332-337.
19.蔡加昌,周宏伟,陈功祥,等.一株耐碳青霉烯类的阴沟肠杆菌的KPC检测.中华医学杂志,2008,88(2):135-138.
20.Cai JC,Zhou HW,Zhang R,et al.Emergence of Serratia marcescens,Klebsiella pneumoniae and Escherichia coli possessing the plasmid-mediated carbapenem-hydrolyzing β-lactamase KPC-2 in intensive care units from a Chinese hospital.Antimicrob Agents Chemother,2008,52(6):2014-2018.
21.季淑娟,顾怡明,谭文涛,等.中国部分地区大肠埃希菌和肺炎克雷伯菌超广谱β-内酰胺酶基因型研究.中华检验医学杂志,2004,27(9):590-593.
22.Shibata N,Doi Y,Yamane K,et al.PCR typing of genetic determinants for metallo-β-lactamases and integrases carried by gram-negative bacteria isolated in Japan,with focus on the class 3 integron.J Clin Microbiol.2003,41(12):5407-5413.
23.Levesque C,Piche L,Larose C,et al.PCR mapping of integrons reveals several novel combinations of resistance genes.Antimicrob Agent Chemother,1995,39(1):185-191.
24.Kaczmarek FM,Dib-Hajj F,Shang W,et al.High-Level carbapenem resistance in a Klebsiella pneumoniae clinical isolate is due to the combination of blaACT-1β-lactamase production,porin OmpK35/36 insertional inactivation,and down-regulation of the phosphate transport porin PhoE.Antimicrob Agents Chemother,2006,50(10):3396-3406.
25.Yigit H,Queenan AM,Anderson GJ,et al.Novel carbapenem-hydrolyzing β-lactamase,KPC-1,from a carbapenem-resistant strain of Klebsiella pneumoniae.Antimicrob Agents Chemother,2001,45(4):1151-1161.
26.Foumier B,Roy PH,Lagrange PH,et al.Chromosomal β-lactamase genes of Klebsiella oxytoca are divided into two main groups,blaOXY-1 and blaOXY-2.Antimicrob Agents Chemother,1996,40(2):454-459.
27.Fournier B,Roy PH.Variability of chromosomally encoded β-lactamases from Klebsiella oxytoca.Antimicrob Agents Chemother,1997,41(8):1641-1648.
28.Hemandez-Alles S,Alberti S,Alvarez D,et al.Porin expression in clinical isolates of Klebsiella pneumoniae.Microbiology,1999,145(3):673-679.
1.Queenan AM,Bush K.Carbapenemases:the versatile β-lactamases.Clin Microbiol Rev,2007,20(3):440-458.
2.Peleg AY,Franklin C,Bell JM,et al.Dissemination of the metallo-β-lactamase gene blaIMP-4 among gram-negative pathogens in a clinical setting in Australia.Clin Infect Dis,2005,41(11):1549-1556.
3.Herbert S,Halvorsen DS,Leong T,et al.Large outbreak of infection and colonization with gram-negative pathogens carrying the metallo-β-lactamase gene blaIMP-4 at a 320-bed tertiary hospital in Australia.Infect Control Hosp Epidemiol,2007,28(1):98-101.
4.Wu JJ,Ko WC,Tsai SH,et al.Prevalence of plasmid-mediated quinolone resistance determinants QnrA,QnrB,and QnrS among clinical isolates of Enterobacter cloacae in a Taiwanese hospital.Antimicrob Agents Chemother,2007,51(4):1223-1227.
5.Liu YF,Yan JJ,Ko WC,et al.Characterization of carbapenem-non-susceptible Escherichia coli isolates from a university hospital in Taiwan.J Antimicrob Chemother,2008,61(5):1020-1023.
6.Wu JJ,Ko WC,Wu HM,et al.Prevalence of Qnr determinants among bloodstream isolates of Escherichia coli and Klebsiella pneumoniae in a Taiwanese hospital,1999-2005.J Antimicrob Chemother,2008,61(6):1234-1239.
7.蔡加昌,周宏伟,陈功祥,等.一株耐碳青霉烯类的阴沟肠杆菌的KPC检测.中华医学杂志,2008,88(2):135-138.
8.季淑娟,顾怡明,谭文涛,等.中国部分地区大肠埃希菌和肺炎克雷伯菌超广谱β-内酰胺酶基因型研究.中华检验医学杂志,2004,27(9):590-593.
9.Shibata N,Doi Y,Yamane K,et al.PCR typing of genetic determinants for metallo-β-lactamases and integrases carried by gram-negative bacteria isolated in Japan,with focus on the class 3 integron.J Clin Microbiol.2003,41(12):5407-5413.
10.Robicsek A,Strahilevitz J,Sahm DF,et al.qnr prevalence in ceftazidime-resistant Enterobacteriaceae isolates from the United States.Antimicrob Agents Chemother.2006,50(8):2872-2874.
11.Jiang Y,Zhou Z,Qian Y,et al.Plasmid-mediated quinolone resistance determinants qnr and aac(6')-Ib-cr in extended-spectrum P-lactamase-producing Escherichia coli and Klebsiella pneumoniae in China.J Antimicrob Chemother.2008,61(5):1003-1006.
12.Deguchi T,Yasuda M,Nakano M,Ozeki S,Kanematsu E,Nishino Y,Ishihara S,Kawada Y.Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.J Antimicrob Chemother.1997,40(4):543-549.
13.Lincopan N,McCulloch JA,Reinert C,et al.First isolation of metallo-P-lactamase-producing multiresistant Klebsiella pneumoniae from a patient in Brazil.J Clin Microbiol,2005,43(1):516-519.
14.Zhang R,Zhou HW,Cai JC,et al.Plasmid-mediated carbapenem-hydrolysing β-lactamase KPC-2 in carbapenem-resistant Serratia marcescens isolates from Hangzhou,China.J Antimicrob Chemother,2007,59(3):574-576.
15.Zhang R,Yang L,Cai JC,et al.High-level carbapenem resistance in a Citrobacter freundii clinical isolate is due to a combination of KPC-2 production and decreased porin expression.J Med Microbiol,2008,57(3):332-337.
16.Cai JC,Zhou HW,Zhang R,et al.Emergence of Serratia marcescens,Klebsiella pneumoniae and Escherichia coli possessing the plasmid-mediated carbapenem-hydrolyzing p-lactamase KPC-2 in intensive care units from a Chinese hospital.Antimicrob Agents Chemother,2008,52(6):2014-2018.
1.董光富,叶任高.尿路感染的分类及致病菌.中国社区医师.2003,19(4):6.
2.Nicolle LE.Epidemiology of urinary tract infection.Infect Med 2001,18:153-162.
3.Orrett FA,Premanand N.Bacteriuria in outpatients with chronic indwelling urethral catheters.Med Sci Res 1993,21:333-334.
4.Bukharie HA,Saeed IM.Antimicrobial resistance among pathogens causing acute uncomplicated UTI.Infect Med 2001,18:358-362.
5.Hooton TM,Stamm WE.Diagnosis and treatment of uncomplicated urinary tract infection.Infect Dis Clin North Am 1997,11:551-581.
6.Ik(a|¨)heimo R,Siitonen A,Heiskanen T,K(a|¨)rkk(a|¨)inen U,Kuosmanen P,Lipponen P,M(a|¨)kel(a|¨) PH.Recurrence of urinary tract infection in a primary care setting:analysis of a 1-year follow-up of 179 women.Clin Infect Dis.1996,22(1):91-99.
7.Orrett FA,Davis GK.A comparison of antimicrobial susceptibility profile of urinary pathogens for the years,1999 and 2003.West Indian Med J.2006,55(2):95-99.
8.Gupta K,Hooton TM,Stamm WE.Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections.Ann Intern Med.2001,3;135(1):41-50.
9.Fihn SD.Clinical practice.Acute uncomplicated urinary tract infection in women.N Engl J Med 2003,349:259-66.
10.Gordon KA,Jones RN;SENTRY Participant Groups(Europe,Latin America,North America).Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America:comparison report to Europe and Latin America.Results from the SENTRY Antimicrobial Surveillance Program(2000).Diagn Microbiol Infect Dis.2003,45(4):295-301.
11.娄美萍,林平.尿路感染常见致病菌及其耐药性分析.实用预防医学,2008,15(2):555-557.
12.Gupta K,Hooton TM,Stamm WE.Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections.Ann Intern Med.2001,135(1):41-50.
13.Hooton TM.Fluoroquinolones and resistance in the treatment of uncomplicated urinary tract infection.Int J Antimicrob Agents.2003,22 Suppl 2:65-72.
14.Warren JW,Abrutyn E,Hebel JR,Johnson JR,Schaeffer AJ,Stamm WE.Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women.Infectious Diseases Society of America(IDSA).Clin Infect Dis.1999,29(4):745-58.
15.耿燕,张王刚,王香玲,杨会斌,黄芳,张毅.泌尿系感染产超广谱β内酰胺酶(ESBL S)大肠埃希菌的耐药表型和基因分型.第四军医大学学报,2005,26(7):622-624.
16.Perilli M,Forcella C,Celenza G,Frascaria P,Segatore B,Pellegrini C,Amicosante G.Evidence for qnrB1 and aac(6')-Ib-cr in CTX-M-15-producing uropathogenic Enterobacteriaceae in an Italian teaching hospital.Diagn Microbiol Infect Dis.2009Feb 25.
17.Casson N,Greub G.Resistance of different Chlamydia-like organisms to quinolones and mutations in the quinoline resistance-determining region of the DNA gyrase A-and topoisomerase-encoding genes.Int J Antimicrob Agents.2006,27(6):541-544.
18.Niwa H,Hobo S,Anzai T.A nucleotide mutation associated with fluoroquinolone resistance observed in gyrA of in vitro obtained Rhodococcus equi mutants.Vet Microbiol.2006,15;115(1-3):264-268.
19.Martinez-Martinez L,Pascual A,Jacoby GA.Quinolone resistance from a transferable plasmid.Lancet.1998,14;351(9105):797-799.
20.Song S,Lee EY,Koh EM,Ha HS,Jeong HJ,Bae IK,Jeong SH.Antibiotic Resistance Mechanisms of Escherichia coli Isolates from Urinary Specimens.Korean J Lab Med.2009,29(1):17-24.
21.Robicsek A,Sahm DF,Strahilevitz J,Jacoby GA,Hooper DC.Broader distribution of plasmid-mediated quinolone resistance in the United States.Antimicrob Agents Chemother.2005,49(7):3001-3003.
22.Kaper JB,Nataro JP,Mobley HL.Pathogenic Escherichia coli.Nat Rev Microbiol.2004,2(2):123-40.
23.Kurazono H,Nakano M,Yamamoto S,Ogawa O,Yuri K,Nakata K,Kimura M,Makino S,Nair GB.Distribution of the usp gene in uropathogenic Escherichia coli isolated from companion animals and correlation with serotypes and size-variations of the pathogenicity island.Microbiol Immunol.2003,47(10):797-802.
24.Gaily DL,Leathart J,Blomfield IC.Interaction of FimB and FimE with the fim switch that controls the phase variation of type 1 fimbriae in Escherichia coli K-12.Mol.Microbiol.1996,21:725-738.
25.Mulvey MA,Lopez-Boado YS,Wilson CL,Roth R,Parks WC,Heuser J,Hultgren SJ.Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli.Science 1998,282 (20):1494-1497.
26.Klumpp DJ,Weiser AC,Sengupta S,Forrestal SG,Batler RA,Schaeffer AJ.Uropathogenic Escherichia coli potentiates type 1 pilus-induced apoptosis by suppressing NF-kappaB.Infect Immun.2001,69(11):6689-6695.
27.Klumpp DJ,Rycyk MT,Chen MC,Thumbikat P,Sengupta S,Schaeffer AJ.Uropathogenic Escherichia coli induces extrinsic and intrinsic cascades to initiate urothelial apoptosis.Infect Immun.2006,74(9):5106-5113.
28.Langermann S,Palaszynski S,Barnhart M,Auguste G,Pinkner JS,Burlein J,Barren P,Koenig S,Leath S,Jones CH,Hultgren SJ.Prevention of mucosal Escherichia coli infection by FimH-Based systemic vaccination.Science,1997,276(25):6072.
29.Kurazono H,Yamamoto S,Nakano M,Nair GB,Terai A,Chaicumpa W,Hayashi H.Characterization of a putative virulence island in the chromosome of uropathogenic Escherichia coli possessing a gene encoding a uropathogenic-specific protein.Microb Pathog.2000,28(3):183-189.
30.Yamamoto S,Nakano M,Terai A,Yuri K,Nakata K,Nair GB,Kurazono H,Ogawa O.The presence of the virulence island containing the usp gene in uropathogenic Escherichia coli is associated with urinary tract infection in an experimental mouse model.J Urol.2001,165(4):1347-1351.
1.Orrett FA,Davis GK.A comparison of antimicrobial susceptibility profile of urinary pathogens for the years,1999 and 2003.West Indian Med J.2006,55(2):95-99.
2.Mulvey MA,Lopez-Boado YS,Wilson CL,Roth R,Parks WC,Heuser J,Hultgren SJ.Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli.Science 1998,282(20):1494-1497.
3.Hooton TM,Scholes D,Hughes JP,Winter C,Roberts PL,Stapleton AE,Stergachis A,Stamm WE.A prospective study of risk factors for symptomatic urinary tract infection in young women.N Engl J Med.1996,335(7):468-474.
4.Hooton TM.Fluoroquinolones and resistance in the treatment of uncomplicated urinary tract infection.Int J Antimicrob Agents.2003,Suppl 2:65-72.
5.Kahlmeter G.The ECO-SENS project:a prospective,multinational,multicentre epidemiological survey of the prevalenceand antimicrobial susceptibility of urinary tract pathogensinterim report.J Antimicrob Chemother 2000,46(Suppl.1):15-22.
6.Kahlmeter G.An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections:the ECO.SENS project.J Antimicrob Chemother 2003,51:69-76.
7.耿燕,张王刚,王香玲,杨会斌,黄芳,张毅.泌尿系感染产超广谱β内酰胺酶(ESBL s)大肠埃希菌的耐药表型和基因分型.第四军医大学学报,2005,26(7):622-624.
8.Urban C,Bradford PA,Tuckman M,Segal-Maurer S,Wehbeh W,Grenner L,Colon-Urban R,Mariano N,Rahal JJ.Carbapenem-resistant Escherichia coli harboring Klebsiella pneumoniae carbapenemase beta-lactamases associated with long-term care facilities.
9.傅辉.尿液细菌对常用抗生素耐药的分析.齐齐哈尔医学院学报,2008,29(16):1992.
10.Orrett FA,Davis GK.A comparison of antimicrobial susceptibility profile of urinary pathogens for the years,1999 and 2003.West Indian Med J.2006,55(2):95-99.
11.Hooton TM,Stamm WE.Diagnosis and treatment of uncomplicated urinary tract infection.Infect Dis Clin North Am 1997,11:551-581.
12.陆坚,唐英春,吴本权,张扣兴,张天托,毕筱刚,朱家馨,谈淑卿.华南地区质粒介导超广谱β-内酰胺酶的基因分型研究.中华微生物学和免疫学杂志.2002,22(6):638-643.
13.季淑娟,顾怡明,谭文涛,王丹丹,冯羡菊,周志慧,俞云松,陈亚岗,李兰娟.中国部分地区大肠埃希菌和肺炎克雷伯菌超广谱β内酰胺酶基因型研究.中华检验医学杂志.2004,27(9):590-593.
14.Bonfiglio G,Perilli M,Stefani S,Amicosante G,Nicoletti G.Prevalence of extended spectrum beta-lactamases among Enterobacteriaceae:an Italian survey.Int J Antimicrob Agents.2002,19(3):213-217.
15.Krcmery S,Dubrava M,Krcmery V Jr.Fungal urinary tract infections in patients at risk.Int J Antimicrob Agents.1999,11(3-4):289-291.
1.董光富,叶任高.尿路感染的分类及致病菌.中国社区医师.2003,19(4):6.
2.Foxman B.Epidemiology of urinary tract infections:incidence,morbidity,and economic costs.Am J Med.113(Suppl 1A):5S-13S.
3.Mysorekar IU,Hultgren SJ.Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract.Proc Natl Acad Sci.2006,103(38):14170-14175.
4.Brauner A,Jacobson SH,Kuhn I.Urinary Escherichia coli causing recurrent infections a prospective follow-up of biochemical phenotypes.Clin Nephrol.1992,38(6):318-323.
5.Kurazono H,Nakano M,Yamamoto S,Ogawa O,Yuri K,Nakata K,Kimura M,Makino S,Nair GB.Distribution of the usp gene in uropathogenic Escherichia coli isolated from companion animals and correlation with serotypes and size-variations of the pathogenicity island.Microbiol Immunol.2003,47(10):797-802.
6.Foxman B,Zhang L,Tallman P,Palin K,Rode C,Bloch C,Gillespie B,Marrs CF.Virulence characteristics of Escherichia coli causing first urinary tract infection predict risk of second infection.J Infect Dis.1995,172(6):1536-1541.
7.Johnson DE,Lockatell CV,Russell RG,Hebel JR,Island MD,Stapleton A,Stamm WE,Warren JW.Comparison of Escherichia coli strains recovered from human cystitis and pyelonephritis infections in transurethrally challenged mice.Infect Immun.1998,66(7):3059-3065.
8.Zhang L,Foxman B,Manning SD,Tallman P,Marrs CF.Molecular epidemiologic approaches to urinary tract infection gene discovery in uropathogenic Escherichia coli.Infect Immun.2000,68(4):2009-2015.
9.Johnson JR.Virulence factors in Escherichia coli urinary tract infection.Clin Microbiol Rev.1991,4(1):80-128.
10.Muhldorfer,I.,Ziebuhr,W.,and Hacker,J.Escherichia coli in Urinary Tract Infections.In:Molecular Medical Microbiology.Sussman,M.(ed.) London:Academic Press,2001,pp.1739-1748.
11.Johnson JR,Stell AL.Extended virulence genotypes of Escherichia coli strains from patients with urosepsis in relation to phylogeny and host compromise.J.Infect.Dis.2000,181:261-272.
12.Bidet P,Mahjoub-Messai F,Blanco J,Blanco J,Dehem M,Aujard Y,Bingen E,Bonacorsi S.Combined multilocus sequence typing and O serogrouping distinguishes Escherichia coli subtypes associated with infant urosepsis and/or meningitis.J Infect Dis.2007,196(2):297-303.
13.Lloyd AL,Rasko DA,Mobley HL.Defining genomic islands and uropathogen-specific genes in uropathogenic Escherichia coli.J Bacteriol.2007,189(9):3532-3546.
14.Clermont O,Bonacorsi S,Bingen E.Rapid and simple determination of the Escherichia coli phylogenetic group.Appl Environ Microbiol.2000,66(10):4555-4558.
15.Bingen E,Picard B,Brahimi N,Mathy S,Desjardins P,Elion J,Denamur E.Phylogenetic analysis of Escherichia coli strains causing neonatal meningitis suggests horizontal gene transfer from a predominant pool of highly virulent B2 group strains.J Infect Dis.1998,177(3):642-50.
16.Boyd EF,Hartl DL Chromosomal regions specific to pathogenic isolates of Escherichia coli have a phylogenetically clustered distribution.J Bacteriol.1998,180(5):1159-1165.
17.Johnson JR.Virulence factors in Escherichia coli urinary tract infection.Clin Microbiol Rev.1991,4(1):80-128.
18.Yamamoto S,Nakano M,Terai A,Yuri K,Nakata K,Nair GB,Kurazono H,Ogawa O.The presence of the virulence island containing the usp gene in uropathogenic Escherichia coli is associated with urinary tract infection in an experimental mouse model.J Urol.2001,165(4):1347-1351.
19.Andrews SC,Robinson AK,Rodriguez-Qui(?)ones F.Bacterial iron homeostasis.FEMS Microbiol Rev.2003,27(2-3):215-237.
20.Gunther NW 4th,Snyder JA,Lockatell V,Blomfield I,Johnson DE,Mobley HL.Assessment of virulence of uropathogenic Escherichia coli type 1 fimbrial mutants in which the invertible element is phase-locked on or off.Infect Immun.2002,70(7):3344-3354.
1.Klumpp DJ,Weiser AC,Sengupta S,Forrestal SG,Batler RA,Schaeffer AJ.Uropathogenic Escherichia coli potentiates type 1 pilus-induced apoptosis by suppressing NF-kappaB.Infect Immun.2001,69(11):6689-6695.
2.Klumpp DJ,Rycyk MT,Chen MC,Thumbikat P,Sengupta S,Schaeffer AJ.Uropathogenic Escherichia coli induces extrinsic and intrinsic cascades to initiate urothelial apoptosis.Infect Immun.2006,74(9):5106-5113.
3.Goluszko P,Popov V,Selvarangan R,Nowicki S,Pham T,Nowicki BJ.Dr fimbriae operon of uropathogenic Escherichia coli mediate microtubule-dependent invasion to the HeLa epithelial cell line.J Infect Dis.1997,176(1):158-167.
4.Gomes TA,Abe CM,Marques LR.Detection of HeLa cell-detaching activity and alpha-hemolysin production in enteroaggregative Escherichia coli strains isolated from feces of Brazilian children.J Clin Microbiol.1995,33(12):3364.
5.Marques LR,Abe CM,Griffin PM,Gomes TA.Association between alpha-hemolysin production and HeLa cell-detaching activity in fecal isolates of Escherichia coli.J Clin Microbiol.1995,33(10):2707-2709.
6.Mills M,Meysick KC,O'Brien AD.Cytotoxic necrotizing factor type 1 of uropathogenic Escherichia coli kills cultured human uroepithelial 5637 cells by an apoptotic mechanism.Infect Immun.2000,68(10):5869-5880.
7.De Rycke J,Gonzalez EA,Blanco J,Oswald E,Blanco M,Boivin R.Evidence for two types of cytotoxic necrotizing factor in human and animal clinical isolates of Escherichia coli.J Clin Microbiol.1990,28(4):694-699.
8.Yamamoto S,Nakano M,Terai A,Yuri K,Nakata K,Nair GB,Kurazono H,Ogawa O.The presence of the virulence island containing the usp gene in uropathogenic Escherichia coli is associated with urinary tract infection in an experimental mouse model.J Urol.2001,165(4):1347-1351.
9.Bouzari S,Jafari A,Farhoudi-Moghaddam AA,Shokouhi F,Parsi M.Adherence of non-enteropathogenic Escherichia coli to HeLa cells.J Med Microbiol.1994,40(2):95-97.
10.Okamoto M,Suzuki M,Kitsuda H,Mihira A,Takahashi C,Akiyama S.Adherence to HeLa cells of Escherichia coli isolated from urinary tract infections.Kitasato Arch Exp Med.1986,59(4):105-114.
11.Laestadius A,Richter-Dahlfors A,Aperia A.Dual effects of Escherichia coli alpha-hemolysin on rat renal proximal tubule cells.Kidney Int.2002,62(6):2035-2042.
12.Miraglia AG,Travaglione S,Meschini S,Falzano L,Matarrese P,Quaranta MG,Viora M,Fiorentini C,Fabbri A.Cytotoxic necrotizing factor 1 prevents apoptosis via the Akt/IkB kinase pathway:role of nuclear factor-kappaB and Bcl-2.Mol Biol Cell.2007,18(7):2735-2744.
13.Hertting O,Chromek M,Slamova Z,Kadas L,Soderkvist M,Vainumae I,Tallvik T,Jacobson SH,Brauner A.Cytotoxic necrotizing factor 1 (CNF1) induces an inflammatory response in the urinary tract in vitro but not in vivo.Toxicon.2008,51(8):1544-1547.
14.Davis JM,Carvalho HM,Rasmussen SB,O'Brien AD.Cytotoxic necrotizing factor type 1 delivered by outer membrane vesicles of uropathogenic Escherichia coli attenuates polymorphonuclear leukocyte antimicrobial activity and chemotaxis.Infect Immun.2006,74(8):4401-4408.
1.Nys S,van Merode T,Bartelds AI,Stobberingh EE.Urinary tract infections in general practice patients:diagnostic tests versus bacteriological culture.J Antimicrob Chemother.2006,57(5):955-958.
2.Gupta K,Hooton TM,Stamm WE.Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections.Ann Intern Med.2001,135(1):41-50.
3.娄美萍,林平.尿路感染常见致病菌及其耐药性分析.实用预防医学.2008,15(2):555-557.
4.董光富,叶任高.尿路感染的分类及致病菌.中国社区医师.2003,19(4):6.
5.Foxman B.Epidemiology of urinary tract infections:incidence,morbidity,and economic costs.Am J Med.113(Suppl 1A):5S-13S.
6.Mysorekar IU,Hultgren SJ.Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract.Proc Natl Acad Sci.2006,103(38):14170-14175.
7.Kurazono H,Nakano M,Yamamoto S,Ogawa O,Yuri K,Nakata K,Kimura M,Makino S,Nair GB.Distribution of the usp gene in uropathogenic Escherichia coli isolated from companion animals and correlation with serotypes and size-variations of the pathogenicity island.Microbiol Immunol.2003,47(10):797-802.
8.刘小梅,沈颖.儿童泌尿系感染大肠杆菌耐药现状.北京医学,2008,30(1):32-34.
9.傅辉.尿液细菌对常用抗生素耐药的分析.齐齐哈尔医学院学报,2008,29(16):1992.
10.Orrett FA,Davis GK.A comparison of antimicrobial susceptibility profile of urinary pathogens for the years,1999 and 2003.West Indian Med J.2006,55(2):95-99.
11.Hooton TM,Stature WE.Diagnosis and treatment of uncomplicated urinary tract infection.Infect Dis Clin North Am 1997,11:551-581.
12.Fihn SD.Clinical practice.Acute uncomplicated urinary tract infection in women.N Engl J Med 2003,349:259-266.
13.Talan DA,Stamm WE,Hooton TM,et al.Comparison of ciprofloxacin(7 days) and trimethoprim-sulfamethoxazole(14 days) for acute uncomplicated pyelonephritis in women:a randomized trial.J Am Med Assoc 2000,283:1583-1590.
14.Urban C,Bradford PA,Tuckman M,Segal-Maurer S,Wehbeh W,Grenner L,Colon-Urban R,Mariano N,Rahal JJ.Carbapenem-resistant Escherichia coli harboring Klebsiella pneumoniae carbapenemase beta-lactamases associated with long-term care facilities.Clin Infect Dis.2008,46(11):e127-130.
15.Hooton TM.Fluoroquinolones and resistance in the treatment of uncomplicated urinary tract infection.Int J Antimicrob Agents.2003,Suppl 2:65-72.
16.Kahlmeter G.The ECO-SENS project:a prospective,multinational,multicentre epidemiological survey of the prevalenceand antimicrobial susceptibility of urinary tract pathogensinterim report.J Antimicrob Chemother 2000,46(Suppl.1):15-22.
17.Kahlmeter G.An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections:the ECO.SENS project.J Antimicrob Chemother 2003,51:69-76.
18.Karlowsky JA,Kelly LJ,Thornsberry C,Jones ME,Sahm DF.Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States.Antimicrob Agents Chemother 2002,46(8):2540-2545.
19.Dromigny JA.,Ndoye B.,Macondo EA.,Nabeth P.,Sihy T.,Perrier-Gros-Claud JD.Increasing prevalence of antimicrobial resistance among Enterobacteriaceae uropathogens in Dakar,Senegal:a multicenter study.Diagn Microbiol Infect Dis 2003,47:595-600.
20.Perilli M,Forcella C,Celenza G,Frascaria P,Segatore B,Pellegrini C,Amicosante G.Evidence for qnrB1 and aac(6')-Ib-cr in CTX-M-15-producing uropathogenic Enterobacteriaceae in an Italian teaching hospital.Diagn Microbiol Infect Dis.2009 Feb 25.[Epub ahead of print]
21.Matrat S,Petrella S,Cambau E,Sougakoff W,Jarlier V,Aubry A.Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.Antimicrob Agents Chemother.2007,51 (5):1643-1648.
22.Sorlozano A,Gutierrez J,Jimenez A,de Dios Luna J,Martinez JL.Contribution of a new mutation in parE to quinolone resistance in extended-spectrum-beta-lactamase-producing Escherichia coli isolates.J Clin Microbiol.2007,45(8):2740-2742.
23.Cattoir V,Lesprit P,Lascols C,Denamur E,Legrand P,Soussy CJ,Cambau E.In vivo selection during ofloxacin therapy of Escherichia coli with combined topoisomerase mutations that confer high resistance to ofloxacin but susceptibility to nalidixic acid.J Antimicrob Chemother.2006,58(5):1054-1057.
24.McMurry L,Petrucci RE Jr,Levy SB.Active efflux of tetracycline encoded by four genetically different tetracycline resistance determinants in Escherichia coli.Proc Natl Acad Sci U S A.1980,77(7):3974-3977.
25.Lomovskaya O,Warren MS,Lee A,Galazzo J,Fronko R,Lee M,Blais J,Cho D,Chamberland S,Renau T,Leger R,Hecker S,Watkins W,Hoshino K,Ishida H,Lee VJ.Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa:novel agents for combination therapy.Antimicrob Agents Chemother.2001,45(1):105-116.
26.Mallea M,Mahamoud A,Chevalier J,Alibert-Franco S,Brouant P,Barbe J,Pages JM.Alkylaminoquinolines inhibit the bacterial antibiotic efflux pump in multidrug-resistant clinical isolates.Biochem J.2003,376(Pt 3):801-805.
27.Mazzariol A,Tokue Y,Kanegawa TM,Cornaglia G,Nikaido H.High-level fluoroquinolone-resistant clinical isolates of Escherichia coli overproduce multidrug efflux protein AcrA.Antimicrob Agents Chemother.2000,44(12):3441-3443.
28.Ribera A,Ruiz J,Jiminez de Anta MT,Vila J.Effect of an efflux pump inhibitor on the MIC of nalidixic acid for Acinetobacter baumannii and Stenotrophomonas maltophilia clinical isolates.J Antimicrob Chemother.2002,49(4):697-698.
29.Soto SM,Smithson A,Martinez JA,Horcajada JP,Mensa J,Vila J.Biofilm formation in uropathogenic Escherichia coli strains:relationship with prostatitis,urovirulence factors and antimicrobial resistance.J Urol.2007,177(1):365-368.
30.Landry RM,An D,Hupp JT,Singh PK,Parsek MR.Mucin-Pseudomonas aeruginosa interactions promote biofilm formation and antibiotic resistance.Mol Microbiol.2006,59(1):142-151.
31.Granslo H,Gammelsrud KW,Fredheim EA,Flaegstad T,Klingenberg C.Coagulase-negative staphylococci--biofilm and antibiotic resistance.Tidsskr Nor Laegeforen.2008,128(23):2746-2749.
32.Bradford PA.Extended spectrumbeta lactamases in the 21 st century:characterization,epidemiology,and detection of this important resistance threat.Clin Mierobiol Rev.2001,14(4):933-951.
33.余方友,傅颖媛,胡龙华,贾坤茹,韩立中,倪语星.多重耐药产PER-1型超广谱β内酰胺酶阴沟肠杆菌的研究.中华检验医学杂志.2005,28(6):642-644.
34.蒋晓飞,倪语星.铜绿假单胞菌产生的超广谱β-内酰胺酶.中华微生物学和免疫学杂志.2001,21S:6-8.
35.袁靖,张淑华.产SHV型超广谱β内酰胺酶不动杆菌的检测及其耐药表型和基因型研究.四川生理科学杂志.2003,25(4):176.
36.贾宁,林茂虎,陈世平,索继江,邢玉斌,江朝光.产超广谱β-内酰胺酶变形杆菌的检测.2003,13(3):207-209.
37.Goossens H.MYSTIC program:surmnary of European data from 1997 to 2000.Diagn Micrebiol Infect Dis.2001,41:183-189.
38.Winkur PL,Canton R,Casellas JM,el at.Variations in the prevalence of strains expressing an extended β-spectrum-laetamases phenotype and characterization of imlmes from Europ,the Americas,and the Westem Pacific region.Clin Infect Dis.2001,32(2):94-103.
39.Yu Y,Zhou W,Chen Y,Ding Y,Ma Y.Epidemiological and antibiotic resistant study on extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Zhejiang Province.Chin Med J(Engl).2002,115(10):1479-1482.
40.陈民钧,王辉.中国重症监护病房革兰阴性菌耐药性连续7年监测研究.中华医学杂志.2003,83:375-381.
41.陆坚,唐英春,吴本权,张扣兴,张天托,毕筱刚,朱家馨,谈淑卿.华南地区质粒介导超广谱β-内酰胺酶的基因分型研究.中华微生物学和免疫学杂志.2002,22(6):638-643.
42.刘文恩,王红梅,唐银.产超广谱β-内酰胺酶细菌感染患者治疗与预后的相关性研究.中华医院感染学杂志.2003,13(8):724-726.
43.Dmsano GL Infection in the intensive unit:beta-lactanmses mediated resistaneeamong Entembaetericase and optimal antimicrobial dosing.Clin Infect Dis,1998,27(Supp-):S111-S116.
44.张兵,钟礼立,蔡瑞云,李云,曾赛珍,黄寒,邹润英,王涛.产超广谱β-内酰胺酶细菌感染的危险因素研究.中国当代儿科杂志.2003,5(2):130-132.
45.季淑娟,顾怡明,谭文涛,王丹丹,冯羡菊,周志慧,俞云松,陈亚岗,李兰娟.中国部分地区大肠埃希菌和肺炎克雷伯菌超广谱β内酰胺酶基因型研究.中华检验医学杂志.2004,27(9):590-593.
46.Paterson DL,Mulazimoglu L,Casellas JM,Ko WC,Goossens H,Von Gottberg A,Mohapatra S,Trenholme GM,Klugman KP,McCormack JG,Yu VL.Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia.Clin Infect Dis.2000,30(3):473-478.
47.Yu WL,Jones RN,Hollis RJ,Messer SA,Biedenbach DJ,Deshpande LM,Pfaller MA.Molecular epidemiology of extended-spectrum beta-lactamase-producing,fluoroquinolone-resistant isolates of Klebsiella pneumoniae in Taiwan.J Clin Microbiol.2002 Dec;40(12):4666-4669.
48.Hong T,Moland ES,Abdalhamid B,Hanson ND,Wang J,Sloan C,Fabian D,Farajallah A,Levine J,Thomson KS.Escherichia coli:development of carbapenem resistance during therapy.Clin Infect Dis.2005,40(10):e84-6.
49.Navon-Venezia S,Chmelnitsky I,Leavitt A,Schwaber MJ,Schwartz D,Carmeli Y.Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel.Antimicrob Agents Chemother.2006,50:3098-101.
50.Staplton PD,Shannon KP,French GL.Carbapenem resistance in Escherichia coli associated with plasmid-mediated CMY beta-lactamase production and loss of an outer membrane protein.Antimicrob Agents Chemother.1999,43:1206-1210.
1.董光富,叶任高.尿路感染的分类及致病菌.中国社区医师.2003,19(4):6.
2.Foxman B.Epidemiology of urinary tract infections:incidence,morbidity,and economic costs.Am J Med.113(Suppl 1A):5S-13S.
3.Mysorekar IU,Hultgren SJ.Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract.Proc Natl Acad Sci.2006,103(38):14170-14175.
4.Brauner A,Jacobson SH,Kuhn I.Urinary Escherichia coli causing recurrent infections a prospective follow-up of biochemical phenotypes.Clin Nephrol.1992,38(6):318-323.
5.Kurazono H,Nakano M,Yamamoto S,Ogawa O,Yuri K,Nakata K,Kimura M,Makino S,Nair GB.Distribution of the usp gene in uropathogenic Escherichia coli isolated from companion animals and correlation with serotypes and size-variations of the pathogenicity island.Microbiol Immunol.2003,47(10):797-802.
6.Hacker J,Blum-Oehler G,Muhldorfer I,et al.Pathogenicity islands of virulent bacteria:structure,function and impact on microbial.Mol.Microbiol.1997,23(10):1089-1097.
7.Johnson JR,Stell AL.Extended virulence genotypes of Escherichia coli strains from patients with urosepsis in relation to phylogeny and host compromise.J.Infect.Dis.2000,181:261-272.
8.McDaniel TK,Jarvis KG,Donnenberg MS,Kaper JB.A genetic locus of enterocyte effacement conserved among diverse enterobacterial pathogens.Proc.Natl.Acad.Sci.USA.1995,92(5):1664-1668.
9.Svanborg Eden,C.Bacterial adherence in urinary tract infections caused by Escherichia coli.Scand.J.Urol.Nephrol.1986,20:81-88.
10.Reid G,Sobel JD.Bacterial adherence in the pathogenesis of urinary tract infection:a review.Rev.Infect.Dis.1987,9:470-487.
11.Svanborg Eden C,Hagberg L,Hanson LA,Hull S,Hull R,Jodal U,Leffler H,Lomberg H,Straube E.Bacterial adherence-a pathogenic mechanism in urinary tract infections caused by Escherichia coli.Prog.Allergy.1983,33:175-188.
12.Schilling JD,Mulvey MA,Hultgren SJ.Structure and function of Escherichia coli type 1 pili:new insight into the pathogenesis of urinary tract infections.J Infect Dis.2001,183 (Suppl 1):S36-40.
13.Olsen P B,Klemm P.Localization of promoters in the fim gene cluster and the effect of H-NS on the transcription of fimB and fimE.FEMS Microbiol.Lett.1994,116:95-100.
14.Klemm P.Two regulatory fim genes.fimB and fimE,control the phase variation of type 1 fimbriae in Escherichia coli.EMBO J.1986,5:1389-1393.
15.Hanson MS,Hempel J,Brinton,Jr CC.Purification of the Escherichia coli type 1 pilin and minor pilus proteins and partial characterization of the adhesin protein.J.Bacteriol.1988,170:3350-3358.
16.Klemm P,Christensen G.Three fim genes required for the regulation of length and mediation of adhesion of Escherichia coli type 1 fimbriae.Mol.Gen.Genet.1987,208:439-445.
17.Gaily DL,Leathart J,Blomfield IC.Interaction of FimB and FimE with the fim switch that controls the phase variation of type 1 fimbriae in Escherichia coli K-12.Mol.Microbiol.1996,21:725-738.
18.Mulvey MA,Lopez-Boado YS,Wilson CL,Roth R,Parks WC,Heuser J,Hultgren SJ.Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli.Science 1998,282 (20):1494-1497.
19.Klumpp DJ,Weiser AC,Sengupta S,Forrestal SG,Batler RA,Schaeffer AJ.Uropathogenic Escherichia coli potentiates type 1 pilus-induced apoptosis by suppressing NF-kappaB.Infect Immun.2001,69(11):6689-6695.
20.Klumpp DJ,Rycyk MT,Chen MC,Thumbikat P,Sengupta S,Schaeffer AJ.Uropathogenic Escherichia coli induces extrinsic and intrinsic cascades to initiate urothelial apoptosis.Infect Immun.2006,74(9):5106-5113.
21.Langermann S,Palaszynski S,Barnhart M,Auguste G,Pinkner JS,Burlein J,Barren P,Koenig S,Leath S,Jones CH,Hultgren SJ.Prevention of mucosal Escherichia coli infection by FimH-Based systemic vaccination.Science,1997,276(25):6072.
22.Langermann S,Mollby R,Burlein JE,Palaszynski SR,Auguste CG,DeFusco A,Strouse R,Schenerman MA,Hultgren SJ,Pinkner JS,Winberg J,Guldevall L,Soderhall M,Ishikawa K,Normark S,Koenig S.Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli.J Infect Dis,2000,181 (2):7742778.
23.Johnson JR.Virulence factors in Escherichia coli urinary tract infection.Clin Microbiol Rev.1991,4(1):80-128.
24.Lund B,Lindberg F,Marklund BI.The PapG protein is the α-D-galactopyranosyl[1(1-4)-β-4]-D-galactopyranose-binding adhesin of uropathogenic Escherichia coli.Proc Natl Acad Sd USA.1987,84(16):5898-5902.
25.Brinton CC.The structure,function,synthesis,and genetic control of bacterial pili and a molecular model for DNA and RNA transport in gram negative bacteria.Trans.N.Y.Acad.Sci.1965,27:1003-1054.
26.Holden N,Totsika M,Dixon L,Catherwood K,Gaily DL.Regulation of P-fimbrial phase variation frequencies in Escherichia coli CFT073.Infect Immun.2007,75(7):3325-3334.
27.Lindberg F,Tennent JM,Hultgren SJ,Lund B,Normark S PapD,a periplasmic transport protein in P-pilus biogenesis.J Bacteriol.1989,171:6052-6058
28.Johnson JR,Brown JJ,Ahmed P.Diversity of hemagglutination phenotypes among P-fimbriated wild-type strains of Escherichia coli in relation to papG allele repertoire.Clin Diagn Lab Immunol.1998,5(2):160-170.
29.Wullt B,Bergsten G,Connell H,Rollano P,Gebretsadik N,Hull R,Svanborg C.P fimbriae enhance the early establishment of Escherichia coli in the human urinary tract.Mol Microbiol.2000,38(3):456-464.
30.Tseng CC,Huang JJ,Wang MC,Wu AB,Ko WC,Chen WC,Wu JJ.PapG Ⅱ adhesin in the establishment and persistence of Escherichia coli infection in mouse kidneys.Kidney Int.2007,71(8):764-770.
31.Rice JC,Peng T,Spence JS,Wang HQ,Goldblum RM,Corthesy B,Nowicki BJ.Pyelonephritic Escherichia coli expressing P fimbriae decrease immune response of the mouse kidney.J Am Soc Nephrol.2005,16(12):3583-3591.
32.Pere A,Leinonen M,Vaisanen-Rhen V,Rhen M,Korhonen TK.Occurrence of type-1C fimbriae on Escherichia coli strains isolated from human extraintestinal infections.J Gen Microbiol.1985,131(7):1705-1711.
33.Khan AS,Kniep B,Oelschlaeger TA,Van Die I,Korhonen T,Hacker J.Receptor structure for F1C fimbriae of uropathogenic Escherichia coli.Infect Immun.2000,68(6):3541-3547.
34.Ott M,Hosch(?)tzky H,Jann K,Van Die I,Hacker J.Gene clusters for S fimbrial adhesin (sfa) and F1C fimbriae (foc) of Escherichia coli:comparative aspects of structure and function.J Bacteriol.1988,170(9):3983-3990.
35.Labigne-Roussel A,Falkow S.Distribution and degree of heterogeneity of the afimbrial-adhesin-encoding operon (afa) among uropathogenic Escherichia coli isolates.Infect Immun.1988,56(3):640-648.
36.Pham TQ,Goluszko P,Popov V,Nowicki S,Nowicki BJ.Molecular cloning and characterization of Dr-Ⅱ,a nonfimbrial adhesin-Ⅰ-like adhesin isolated from gestational pyelonephritis-associated Escherichia coli that binds to decay-accelerating factor.Infect Immun.1997,65(10):4309-4318.
37.Foxman B,Zhang L,Tallman P,Palin K,Rode C,Bloch C,Gillespie B,Marrs CF.Virulence characteristics of Escherichia coli causing first urinary tract infection predict risk of second infection.J Infect Dis.1995,172(6):1536-1541.
38.Nowicki B,Selvarangan R,Nowicki S.Family of Escherichia coli Dr adhesins:decay-accelerating factor receptor recognition and invasiveness.J Infect Dis.2001,183 Suppl 1:S24-27.
39.Goluszko P,Popov V,Selvarangan R,Nowicki S,Pham T,Nowicki BJ.Dr fimbriae operon of uropathogenic Escherichia coli mediate microtubule-dependent invasion to the HeLa epithelial cell line.J Infect Dis.1997,176(1):158-167.
40.Smith HW.The haemolysins of Escherichia coli.J Pathol Bacteriol.1963,85:197-211.
41.Walton JR,Smith DH.New hemolysin (gamma) produced by Escherichia coli.J Bacteriol.1969,98(1):304-305.
42.Felmlee T,Pellett S,Welch RA.Nucleotide sequence of an Escherichia coli chromosomal hemolysin.J Bacteriol.1985,163(1):94-105.
43.Bhakdi S,Mackman N,Nicaud JM,Holland IB.Escherichia coli hemolysin may damage target cell membranes by generating transmembrane pores.Infect Immun.1986,2(1):63-69.
44.Jorgensen SE,Mulcahy PF,Wu GK,Louis CF.Calcium accumulation in human and sheep erythrocytes that is induced by Escherichia coli hemolysin.Toxicon.1983,21(5):717-27.
45.Rennie RP,Freer JH,Arbuthnott JP.The kinetics of erythrocyte lysis by Escherichia coli haemolysin.J Med Microbiol.1974,7(2):189-195.
46.Smith YC,Rasmussen SB,Grande KK,Conran RM,O'Brien AD.Hemolysin of uropathogenic Escherichia coli evokes extensive shedding of the uroepithelium and hemorrhage in bladder tissue within the first 24 hours after intraurethral inoculation of mice.Infect Immun.2008.76(7):2978-2990.
47.Smith YC,Grande KK,Rasmussen SB,O'Brien AD.Novel three-dimensional organoid model for evaluation of the interaction of uropathogenic Escherichia coli with terminally differentiated human urothelial cells.Infect Immun.2006,74(1):750-757.
48.Mobley HL,Green DM,Trifillis AL,Johnson DE,Chippendale GR,Lockatell CV,Jones BD,Warren JW.Pyelonephritogenic Escherichia coli and killing of cultured human renal proximal tubular epithelial cells:role of hemolysin in some strains.Infect Immun.1990,58(5):1281-1289.
49.Warren JW,Mobley HL,Hebel JR,Trifillis AL.Cytolethality of hemolytic Escherichia coli to primary human renal proximal tubular cell cultures obtained from different donors.Urology.1995,45(4):706-710.
50.Laestadius A,Richter-Dahlfors A,Aperia A.Dual effects of Escherichia coli alpha-hemolysin on rat renal proximal tubule cells.Kidney Int.2002,62(6):2035-2042.
51.De Rycke J,Gonzalez EA,Blanco J,Oswald E,Blanco M,Boivin R.Evidence for two types of cytotoxic necrotizing factor in human and animal clinical isolates of Escherichia coli.J Clin Microbiol.1990,28(4):694-699.
52.Landraud L,Gauthier M,Fosse T,Boquet P.Frequency of Escherichia coli strains producing the cytotoxic necrotizing factor (CNF1) in nosocomial urinary tract infections.Lett Appl Microbiol.2000,30(3):213-216.
53.Andreu A,Stapleton AE,Fennell C,Lockman HA,Xercavins M,Fernandez F,Stamm WE.Urovirulence determinants in Escherichia coli strains causing prostatitis.J Infect Dis.1997,176(2):464-469.
54.Rippere-Lampe KE,Lang M,Ceri H,Olson M,Lockman HA,O'Brien AD.Cytotoxic necrotizing factor type 1-positive Escherichia coli causes increased inflammation and tissue damage to the prostate in a rat prostatitis model.Infect Immun.2001,69(10):6515-6519.
55.Falzano L,Fiorentini C,Donelli G,Michel E,Kocks C,Cossart P,Cabanie L,Oswald E,Boquet P.Induction of phagocytic behaviour in human epithelial cells by Escherichia coli cytotoxic necrotizing factor type 1.Mol Microbiol.1993,9(6):1247-1254.,
56.Fiorentini C,Fabbri A,Matarrese P,Falzano L,Boquet P,Malorni W.Hinderance of apoptosis and phagocytic behaviour induced by Escherichia coli cytotoxic necrotizing factor 1:two related activities in epithelial cells.Biochem Biophys Res Commun.1997,18;241(2):341-346.
57.Mills M,Meysick KC,O'Brien AD.Cytotoxic necrotizing factor type 1 of uropathogenic Escherichia coli kills cultured human uroepithelial 5637 cells by an apoptotic mechanism.Infect Immun.2000,68(10):5869-5880.
58.Miraglia AG,Travaglione S,Meschini S,Falzano L,Matarrese P,Quaranta MG,Viora M,Fiorentini C,Fabbri A.Cytotoxic necrotizing factor 1 prevents apoptosis via the Akt/IkB kinase pathway:role of nuclear factor-kappaB and Bcl-2.Mol Biol Cell.2007,18(7):2735-2744.
59.Hertting O,Chromek M,Slamova Z,Kadas L,Soderkvist M,Vainumae I,Tallvik T,Jacobson SH,Brauner A.Cytotoxic necrotizing factor 1 (CNF1) induces an inflammatory response in the urinary tract in vitro but not in vivo.Toxicon.2008,51(8):1544-1547.
60.Davis JM,Carvalho HM,Rasmussen SB,O'Brien AD.Cytotoxic necrotizing factor type 1 delivered by outer membrane vesicles of uropathogenic Escherichia coli attenuates polymorphonuclear leukocyte antimicrobial activity and chemotaxis.Infect Immun.2006,74(8):4401-4408.
61.Earhart,C.F.Uptake and metabolism of iron and molybdenum,1996,p.1075-1090.In F.C.Neidhardt (ed.),Escherichia coli and Salmonella.ASM Press,Washington,D.C.
62.Schubert,S.,A.Rakin,H.Karch,E.Carniel,and J.Heeseman.Prevalence of the “high pathogenicity island”of Yersinia species among Escherichia coli strains that are pathogenic to humans.Infect.Immun.1998,66:480-485.
63.Russo TA,Carlino UB,Mong A,Jodush ST.Identification of genes in an extraintestinal isolate of Escherichia coli with increased expression after exposure to human urine.Infect Immun.1999,67(10):5306-5314.
64.Torres AG,Redford P,Welch RA,Payne SM.TonB-dependent systems of uropathogenic Escherichia coli:aerobactin and heme transport and TonB are required for virulence in the mouse.Infect Immun.2001,69(10):6179-6185.
65.Jann K,Jann B.Capsules of Escherichia coli,expression and biological significance.Can J Microbiol.1992,38(7):705-710.
66.Whitfield C,Roberts IS.Structure,assembly and regulation of expression of capsules in Escherichia coli.Mol Microbiol.1999,31(5):1307-13019.
67.Tiba MR,Yano T,Leite Dda S.Genotypic characterization of virulence factors in Escherichia coli strains from patients with cystitis.Rev Inst Med Trop Sao Paulo.2008,50(5):255-260.
68.Schneider G,Dobrindt U,Br(?)ggemann H,Nagy G,Janke B,Blum-Oehler G,Buchrieser C,Gottschalk G,Emody L,Hacker J.The pathogenicity island-associated K15 capsule determinant exhibits a novel genetic structure and correlates with virulence in uropathogenic Escherichia coli strain 536.Infect Immun.2004 Oct;72(10):5993-6001.
69.Kubori T,Matsushima Y,Nakamura D,Uralil J,Lara-Tejero M,Sukhan A,Galan JE,Aizawa SI.Supramolecular structure of the Salmonella typhimurium type Ⅲ protein secretion system.Science.1998,280(5363):602-605.
70.Miyazaki J,Ba-Thein W,Kumao T,Akaza H,Hayashi H.Identification of a type Ⅲ secretion system in uropathogenic Escherichia coli.FEMS Microbiol Lett.2002,212(2):221-228.
71.Nakano M,Yamamoto S,Terai A,Ogawa O,Makino SI,Hayashi H,Nair GB,Kurazono H.Structural and sequence diversity of the pathogenicity island of uropathogenic Escherichia coli which encodes the USP protein.FEMS MicrobiolLett.2001,205(1):71-76.
72.Kurazono H,Yamamoto S,Nakano M,Nair GB,Terai A,Chaicumpa W,Hayashi H.Characterization of a putative virulence island in the chromosome of uropathogenic Escherichia coli possessing a gene encoding a uropathogenic-specific protein.Microb Pathog.2000,28(3):183-189.
73.Yamamoto S,Nakano M,Terai A,Yuri K,Nakata K,Nair GB,Kurazono H,Ogawa O.The presence of the virulence island containing the usp gene in uropathogenic Escherichia coli is associated with urinary tract infection in an experimental mouse model.J Urol.2001,165(4):1347-1351.
74.Nicoletti M,Superti F,Conti C,Calconi A,Zagaglia C.Virulence factors of lactose-negative Escherichia coli strains isolated from children with diarrhea in Somalia.J Clin Microbiol.1988,26(3):524-529.